Title Page

Full Title: Effect of early glycaemic control on HbA1c tracking and development of vascular complications after 5 years of childhood onset type 1 diabetes: Systematic Review and Meta-analysis

Short running title: Early glycaemic control and later outcomes.

Veena Mazarello Paes^{1, 2}, Jessica K Barrett³, David C Taylor-Robinson⁴, Heather Chesters¹, Dimitrios Charalampopoulos¹, David B Dunger^{2,5}, Russell M Viner⁶, Terence J Stephenson¹

¹Great Ormond Street Institute of Child Health, University College London, UK
²Department of Paediatrics, University of Cambridge, UK
³MRC Biostatistics Unit, University of Cambridge, UK
⁴University of Liverpool, UK
⁵Wellcome Trust - MRC Institute of Metabolic Sciences, University of Cambridge, UK
⁶The Royal College of Paediatrics and Child Health, London, UK

Authors details:

Veena Mazarello Paes MSc, MPH, MPhil, PhD
 UCL Great Ormond Street Institute of Child Health,
 London WC1N 1EH, UK
 Department of Paediatrics,
 University of Cambridge,

Cambridge, UK

Jessica K Barrett MSc, PhD
 MRC Biostatistics Unit,
 University of Cambridge,
 Cambridge, UK
 Email: jkb23@medschl.cam.ac.uk

David C Taylor-Robinson MB ChB, MPH, PhD, FFPH, MRCPCH
 Department of Public Health and Policy
 University of Liverpool,
 Liverpool, UK
 Email: david.taylor-robinson@liverpool.ac.uk

4. Heather Chesters MA, MCLIP
UCL Great Ormond Street Institute of Child Health Library
UCL Great Ormond Street Institute of Child Health,
London WC1N 1EH, UK
Email: h.chesters@ucl.ac.uk

5. Dimitrios Charalampopoulos MD, MPhil, PhD

UCL Great Ormond Street Institute of Child Health,

London WC1N 1EH, UK

Email: d.charalampopoulos@ucl.ac.uk

6. David B Dunger MD, FMedSci, FRCPCH
Department of Paediatrics,
University of Cambridge,
Cambridge, UK
Wellcome Trust - MRC Institute of Metabolic Sciences,
University of Cambridge,
Cambridge, UK
Email: dbd25@cam.ac.uk

7. Russell M Viner MBBS, PhD, FRCPCH

UCL Great Ormond Street Institute of Child Health,

London, UK

The Royal College of Paediatrics and Child Health

London, UK

Email: r.viner@ucl.ac.uk

8. Terence J Stephenson DM, FRCPCH

UCL Great Ormond Street Institute of Child Health,

London, UK

Email: t.stephenson@ucl.ac.uk

Corresponding author:

Veena Mazarello Paes

UCL Great Ormond Street Institute of Child Health, 1st floor, Wellcome Trust Building, 30 Guilford Street London WC1N 1EH UK Tel: +44 (0)20 7905 2805 Email: veena.paes.14@ucl.ac.uk

Word count: abstract: 250 and main text (excluding references): 4430

Number of tables: 2

Number of additional files: 5

Number of figures: 3

Number of supplementary figures: 3

Effect of early glycaemic control on HbA1c tracking and development of vascular complications after 5 years of childhood onset type 1 diabetes: Systematic Review and Meta-analysis.

ABSTRACT

Objective: A systematic review and meta-analysis was conducted to investigate if glycaemic control measured by glycated Haemoglobin (HbA1c) levels near diagnosis are predictive of future glycaemic outcomes and vascular complications in childhood onset type 1 diabetes (T1D).

Methods: Evidence was gathered using electronic databases (MEDLINE, EMBASE, Web of Science, CINAHL, Scopus and Cochrane Library up to February 2017) and snowballing techniques. Studies investigating the association between the exposure "early glycaemic control" and main outcome: "tracking of early control" and secondary outcome: risk of future complications; in children and young people aged 0 to 19 years at baseline; were systematically double-reviewed, quality assessed and outcome data extracted for synthesis and meta-analysis.

Findings: Five studies (N=4227 participants) were eligible. HbA1c levels were suboptimal throughout the study period but tended to stabilise in a "track" by 6 months after T1D diagnosis. The group with low HbA1c <53mmol/mol (<7%) at baseline had lower long-term HbA1c levels than the higher HbA1c group. The estimated standardised mean difference between the sub groups showed a reduction of HbA1c levels on average by 1.6% (range -0.95 to -2.28%) from baseline. Only one study investigated the association between early glycaemic control and development of vascular complications in childhood onset T1D.

Interpretations: Glycaemic control after the first few months of childhood onset T1D, remains stable but sub-optimal for a decade. The low and high HbA1c levels at baseline seem to "track" in their respective tracks during the 10-year follow-up however, the initial difference between groups narrows over time.

PROSPERO:CRD42015024546

http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015024546

INTRODUCTION

Glycated haemoglobin (HbA1c) levels, a measure for glycaemic control is the main predictor of long-term type 1 diabetes (T1D) outcomes (1-3). HbA1c levels are highest at diagnosis, but improve after insulin treatment and remain stable in most T1D patients. However, a few find it challenging to maintain good glycaemic control despite targeted or intensive interventions, as they go through various stages in life (4, 5).

Studies mainly in adults have shown a link between poor glycaemic control in the early phase following T1D diagnosis and long-term HbA1c levels, with an increased risk of developing vascular complications and mortality (6, 7). The risk of vascular complications is likely to be greater for childhood onset T1D, due to a longer duration of glycaemic exposure (8) and pathophysiological factors such as reduced insulin sensitivity and psychosocial behaviours such as insulin omission (9-11). For childhood onset T1D, some observational studies indicate an association between poor glycaemic control within one or two years of diagnosis and vascular complications in later life (12-14). Others suggest that mean HbA1c levels nearer to diagnosis are predictive of HbA1c levels in the subsequent years, even lifetime, regardless of the type of insulin regimen (15-17). This phenomenon, also known as glycaemic "tracking", is poorly understood (18). It is unclear exactly when and in whom the phenomenon of "tracking" of HbA1c occurs in childhood onset T1D and if it is due to the natural history of T1D. It is therefore important to investigate the evidence on this phenomenon in order to identify if there exists a window period in the initial phase of T1D diagnosis, during which appropriate resources could be mobilised to deliver targeted interventions to those at risk of developing poorer long-term glycaemic outcomes and vascular complications.

The purpose of our study was to carry out a systematic review and meta-analysis of the evidence assessing the impact of early glycaemic control in children (followed for at least 5 years from diagnosis) on tracking of early control and the risk of developing vascular complications.

METHODS

This review is part of a series of systematic reviews of evidence on the effects of early glycaemic control in childhood onset T1D. The review protocol was registered in PROSPERO (Registration number: CRD42015024546) and a detailed protocol published (19). We followed the review methods for the rigorous conduct and reporting of systematic reviews for policy and practice as described by the Evidence for Policy and Practice Information (EPPI) Centre (20) which are as per PRISMA guidelines (21).

Search strategy

A refined search strategy was designed after a number of initial iterative scoping searches, with input from experts in the field to maximize capturing of key publications. Three sets of search terms were used relating to population (children and young people diagnosed with T1D), exposure (terms to capture observational, intervention, qualitative studies and review articles relating to early diabetes control) and outcome (complications, mortality, glycaemic tracking i.e. metabolic memory) (additional file 1). Six electronic databases: (MEDLINE and EMBASE via OVID, Web of Science via Thompson Reuters, CINAHL Plus via EBSCO, Scopus via Elsevier and the Cochrane Library), were double searched in parallel by HC & VMP from inception to December 2014 and updated in February 2017 by using a combination of free text and Thesaurus

or MeSH terms (additional file 2). No time-period or language restrictions were applied. All identified articles from electronic databases were imported into Endnote and deduplicated for further review. This was supplemented by hand-searching of reference lists of studies and reviews, grey literature, personal databases and contacting experts and authors of included studies for additional or unpublished data.

Study selection

Interventional and observational studies with a follow-up of \geq 5 years from diagnosis of T1D which described and quantified the association between early glycaemic control (defined as glycaemic control within 2 years of diagnosis of T1D) AND longterm glycaemic tracking (defined as settling of HbA1c levels into long-term tracks of either > or < 7% i.e. 53 mmol/mol) and risk of future complications in children and young people aged 0 to 19 years at baseline were included (Additional file 3).

In addition to running electronic database searches in parallel (HC and VMP), subsamples of papers were double-reviewed (DC and VMP), at each stage of the review process (title and abstract screening, data extraction and quality assessment). The interrater reliability for study selection was substantial (22). Full texts of abstracts appearing to meet the inclusion criteria were retrieved and their status was recorded in a pre-piloted excel spread-sheet, which included specific study details and reasons for exclusion (for excluded studies). No foreign language papers were identified. Articles were re-examined (DC and VMP) if there was uncertainty about inclusion criteria and disagreements were resolved at team meetings.

Data extraction

Data from included studies were extracted, analysed and synthesised by one reviewer (VMP). A proportion of shortlisted studies were also independently double reviewed and data extracted (DC & RA). From observational studies, data on HbA1c levels were extracted at all available time points from diagnosis. Data on HbA1c tracking and the association between early glycaemic control and chronic complications or markers of chronic complications at follow-up were extracted (additional file 4). Authors of included studies were contacted for clarity and additional information on HbA1c tracking of early glycaemic control based on HbA1c measurements as percentage (DCCT) and/or mmol/mol (International Federation of Clinical Chemistry) units. The secondary outcome of interest was the impact of early glycaemic control on the development of micro and macro vascular complications during the long-term follow-up period.

Quality assessment

The quality of included studies was assessed independently by two reviewers (DC and VMP) using the quality assessment criteria by the EPPI Centre (20). Any disagreements were resolved by consensus. Scores were based on six items focusing on both internal and external validity (additional file 5). Observational studies were classified as high (\geq 5), intermediate (3-4) or low (\leq 2) quality based on the number of quality criteria met out of a maximum assessment score of six.

Statistical analysis

Information extracted from included studies were summarised through descriptive narrative synthesis and meta-analysis (23). All statistical analyses were conducted by one reviewer (VMP) and were verified by a second reviewer (JB). The sample size,

mean HbA1c measurements and standard deviation (SD) or standard error (SE) were available at population level and/or for categorised low and high HbA1c groups. Where not reported, the SE of the study at each time point was calculated using the reported SD and the group sample sizes. Baseline period included 3-6 months from T1D diagnosis. Mean HbA1c levels at diagnosis was not included in the main meta-analysis as by definition they were measured prior to exposure of glycaemic control with insulin therapy. The effect sizes and their SE were divided with SD to obtain standardised mean differences (SMD) (24).

The primary outcome was the population mean HbA1c level at baseline (0, 3, 6 months of diagnosis), 1, 2, 3, 5, 7 and 10 years follow up. A further primary outcome was the difference in HbA1c levels between the low HbA1c (<7% at baseline) group (considered the 'treated/exposed' group) and the high HbA1c group (\geq 7% at baseline) (the 'control' group), reported as standardised mean differences. If multiple measurements of HbA1c were reported at follow-up then these measures were combined within each study before meta-analysis. Heterogeneity between studies was expected and therefore both fixed effects (FE, inverse variance) and random effects (RE, Dersimonian and Laird) models were used to pool the effect sizes and reported using forest plots (25). The heterogeneity between studies was assessed using the χ^2 test for heterogeneity and I² statistics (26). The meta-analyses were carried using the metan command in STATA 15, StataCorp, College Station, Texas 77845 USA.

For glycated haemoglobin, the estimated pooled standardised mean differences were converted into absolute units, to facilitate clinical interpretation, by multiplying the estimate by the pooled SD of all included studies of the meta-analysis. Furthermore, the long-term population average HbA1c trajectory from each study was plotted alongside the overall estimate at all-time points of follow-up obtained from the meta-analysis. The trajectories of HbA1c sub groups (low v/s high) in each study were also plotted.

The robustness of the meta-analysis to the choice of meta-analysis model was assessed by comparing FE and RE pooled standardised effect sizes. In a sensitivity analysis we excluded studies in pre-school children.

Assessing publication bias using the funnel plots, the Begg's rank correlation test or the Egger's linear regression test was deemed inappropriate as there were insufficient studies included in the review.

Due to the small number of included studies, meta-regression was not appropriate to explore heterogeneity between studies or to investigate if there were other potential factors that could be independently associated with long-term glycaemic control. A minimum of 10 studies per study level parameter would be needed for metaregression.

Only one included study assessed the association of micro and macro-vascular complications with early glycaemic control, which precluded a meta-analysis and results of which were narrated separately.

RESULTS

The literature search strategy on glycaemic control in childhood onset T1D identified articles from individual databases (Medline via OVID, n = 14,688; Embase via OVID, n = 843; Web of Science via Thompson Reuters, n = 2,734; CINAHL Plus via EBSCO, n = 1,185; Scopus via Elsevier, n = 2,837 and Cochrane library, n = 4,052). After deduplication 21,063 articles were screened, out of which 390 were shortlisted for full review (Figure 1). There was good agreement between reviewers on identifying abstracts for full text review. 385 studies were excluded from the systematic review and meta-analysis for reasons shown in figure 1. Five fairly recent studies (24, 27-30) conducted in developed countries (Israel, Scotland, Sweden and USA) with a total of 4227 participants met the inclusion criteria of the systematic review. The studies investigated national (24), regional (27), Children's hospital (29), academic medical centre (30) and clinic (28) level data.

Characteristics of included studies

The Swedish cohort study (24) consisted of 1543 children and adolescents (920 males) from two nationwide population-based Swedish registries (Swedish Paediatric Quality Registry and Swedish National Diabetes Register) covering a period from year 2000 to 2010. The mean age at diagnosis was 13.9 (range 5.0 to 19.0) years and the mean follow-up was for 7.1 \pm 2.5 (range 1.0 to 12.0) years. The study investigated whether high mean HbA1c values 3-15 months after diagnosis of T1D in childhood was associated with future glycaemic control, albuminuria and retinopathy in early adulthood.

The American study (29) prospectively investigated, between the years 1993 and 2009, whether age at diagnosis, gender, ethnicity, diagnostic era (year of diagnosis)

and type of insulin therapy were associated with tracking of glycaemic control at five years follow-up post diagnosis of T1D. A total of 2218 (1166 males) mainly nonhispanic Caucasian (86.1%) children and adolescents participants with a mean age of 9.0 ±4.1 years at diagnosis (range 0 to 20 years), were identified from the Children's Mercy Hospital Type 1 diabetes in paediatrics database, USA. Insulin therapy (split regimen dosing, multiple daily injections and continuous subcutaneous insulin infusion) and diagnostic methods used to analyse HbA1c varied during the study period. Information on the socio-economic status and T1D history in family was not reported.

The other American study (30) followed 138 children (71% males and 91.5% white) at an academic medical centre of Pediatric Endocrinology/Diabetology at Riley Hospital for Children, Indiana, USA and investigated whether long term HbA1c differed as a result of receiving diabetes related education during the years 1998-2002. The mean age at diagnosis was 6.8 ± 3.3 years (age range: 1.1 - 13.9 years). Details of insulin therapy was not reported.

The Scottish study (27) retrospectively investigated HbA1c tracking among 155 children (74 males), aged \leq 16 years (range 0 to 16 years), from the regional database of the National Health Service (NHS) Highland Paediatric diabetic services followed for a median of 4.10 (range 0 to 15.0) years from diagnosis between the years 1993 and 2012. The cohort had limited ethnic diversity, low use of intensive insulin therapy and no use of pump therapy.

The Israeli study (28) was a retrospective observational study, investigating HbA1c tracking in 173 mainly Jewish (84.4%) preschool aged children (84 males) aged 0.5 – 6.5 years at diagnosis between 1993 and 2009 at a tertiary level diabetes clinic in Israel, with a median T1D duration of 4.3 years (range 1 to 11 years) and followed up for seven years from T1D onset. All patients were advised on carbohydrate counting, required to perform >6 self- blood glucose measurements per day and both multiple daily injections and insulin pumps were used.

Further details of the data extracted from the five studies included in the systematic review are in Table 1.

Study Quality

The quality of the observational studies was intermediate to high. Two studies were assessed to be "high" quality with a score of five each (24, 29) and the other three were of "intermediate" quality, with scores of four (27, 30) and three (28) out of a possible score of six respectively. No studies included in the review were of low quality.

Early HbA1c levels and long-term tracking of glycaemic control

All five studies included in the review assessed the association between early glycaemic control and later HbA1c levels. Population mean HbA1c was available at various follow-up time points (0, 3, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 156 months after T1D diagnosis). Additionally, four studies provided data on the association between early glycaemic control and later HbA1c levels within sub groups of low and high HbA1c identified at baseline (24, 27-29).

To study the impact of early glycaemic control on later HbA1c levels, data from all five studies could be pooled in the review. The number of studies reporting the effect during each time point of the study period varied. All studies reported sub-optimal estimated mean long-term glycaemic control at all of the investigated time points during the 10-year follow-up period. The sample size varied from 25 to 2218 and the study periods ranged between years 1993 and 2012. After using the population mean HbA1c and SE in the FE & RE models, the estimated pooled magnitude of the mean HbA1c levels (95% Cl) was suboptimal at 11.56% (Cl: 11.46, 11.66%) at diagnosis, 7.74% (Cl: 7.68, 7.80%) after 3 months 7.61% (Cl: 7.47, 7.76%) after 6 months, 7.79% (Cl: 7.71, 7.87%) after 1 year, 7.90%(Cl: 7.83, 7.98%) after 2 years, 7.94% (Cl: 7.86, 8.03%) after 3 years, 8.57% (Cl: 8.49, 8.65%) after 5 years, 7.99% (Cl: 7.85, 8.12%) after 7 years and 8.59%(Cl: 8.24, 8.94%) after 10 years of T1D diagnosis.

The pooled results comparing the effect size results of the FE and RE models were presented in forest plot (Figure 2) and the overall effect estimates were also presented in a graph (supplementary Figure 2). There was variation in glycaemic control between countries in children and adolescents during the 10-year study period. The test for heterogeneity between studies was significantly high ($l^2 > 69\%$) at almost all of the follow-up time points in the meta-analysis ($\chi^2 p < 0.05$).

Further exploratory sub-group analysis indicates that heterogeneity was consistently high between studies, countries and populations.

For the assessment of early glycaemic control (low and high HbA1c identified at baseline) and what followed at various time points during the study period, there were

four studies with data that could be pooled in the review. The HbA1c levels of the low HbA1c group showed better improvement than the high HbA1c group during the study period. The low and high Hba1c levels at baseline seem to "track" in their respective tracks during the 10-year follow-up however, the initial difference between groups narrows over time (Figure 3).

From the FE meta-analysis, the pooled standardised difference in mean HbA1c levels between patients in the low HbA1c group and those in the high HbA1c group with 95% CI was significant at -1.25 (-1.53, -0.97) after 6 months, -0.85 (-0.95, -0.75) after 1 year, -0.84 (-0.95, -0.74) after 2 years, -0.78 (-0.89, -0.66) after 3 years, -0.44 (-0.54, -0.34) after 5 years, -0.75 (-0.94, -0.55) after 7 years and -0.32 (-0.63, -0.02) after 10 years of T1D diagnosis. The treatment effect in absolute units was a reduction of HbA1c levels on average by 1.6% (range -0.95 to -2.28%) from baseline, which may be clinically relevant (Table 2).

The study in pre-school aged children (mean age at diagnosis 3.8 ± 1.6 years) showed better control than the other studies with older children (28).The heterogeneity levels were significantly high (p=0.001) at 1, 2, 3 and 5 years after diagnosis and were lower at follow-up time points 0.5, 7 and 10 years after diagnosis (p>0.7) in the metaanalysis.

The meta-analysis was repeated after excluding the study in pre-school aged children (Supplementary figure 1). The pooled standardised mean difference in HbA1c levels between patients in the low HbA1c group and those in the high HbA1c group with 95% CI was slightly lower at -1.10 (-1.56, -0.65) after 6 months, -0.79 (-0.89, -0.69) after 1

year, -0.78 (-0.89, -0.67) after 2 years, -0.71 (-0.83, -0.59) after 3 years, -0.41 (-0.51, -0.30) after 5 years, -0.72 (-0.92, -0.53) after 7 years and -0.32 (-0.63, -0.02) after 10 years of T1D diagnosis. The treatment effect in absolute units was a reduction of HbA1c levels on an average by 1.49% (range -0.90 to -2.37%) from baseline. The test for heterogeneity showed improved results and was significantly high only at 5 years after diagnosis (p=0.001) in the meta-analysis (Table 2).

Comparing the long-term HbA1c trajectories between studies revealed that the Israeli study in pre-school children yielded better long-term control (supplementary Fig 2). Individual study results suggest that early glycaemic control tracks during the follow-up in the initially low and high HbA1c groups (Supplementary Fig 3)

Since there were only 5 studies in the review, we could not assess publication bias using the funnel plot, the Begg adjusted rank correlation test or the Egger test as there was insufficient power to distinguish real asymmetry from random chance.

Association of early HbA1c levels and complications risk

Only one longitudinal study (24) investigated the association of early glycaemic control and future complications and met the inclusion criteria for the systematic review. The study, adjusted for gender, T1D duration, age at diagnosis, physical activity and smoking) and reported that Swedish children with higher mean HbA1c levels of \ge 8.7% (\ge 70 mmol/mol), 3-15 months after diagnosis were significantly more likely to develop macroalbuminuria (OR: 14.3, 95% CI: 2.6 to 78.2, p<0.01), microalbuminuria (OR: 1.7, 95% CI: 0.8 to 3.4, p<0.05) and retinopathy (OR: 2.0, 95% CI: 1.2 to 3.1, p<0.01) in early adulthood (mean age: 21± 2.3 years, range: 18 to 29 years). The study also highlighted the lack of physical activity, smoking and female gender as predictors of poor glycaemic control. However, the role of insulin therapies and other social and family factors on these observations was not reported.

DISCUSSION

We identified five longitudinal studies investigating the impact of early glycaemic control on long-term glycaemic control in children and adolescents (<19 years) followed from diagnosis of T1D. In the meta-analysis of all included 5 studies, the overall mean HbA1c levels in all studies were sub-optimal at all follow-up time points.

The meta-analysis of the four studies comparing initially low v/s high HbA1c groups, indicates that the low HbA1c group showed overall slightly improved control than the high HbA1c group during the study period. Additionally, the meta-analyses suggests that the overall glycaemic control was stable in a "track" after 6 months of childhood onset T1D diagnosis. The low and high HbA1c levels at baseline also seem to "track" in their respective tracks during the 10-year follow-up. However, the initial difference between groups narrows over time. The number of participants in the low HbA1c group was small and this may have influenced the power to detect group differences.

Three of the included studies were of intermediate quality while the remaining two were of high quality in reporting potential biases. We adhered to strict systematic review procedures for study selection, data extraction and reporting to minimise reviewer related biases. The age ranges and sample sizes varied between studies which may have influenced the heterogeneity seen in the pooled estimates of longterm glycaemic control. Heterogeneity was reduced when the study in pre-school children was excluded from the meta-analysis.

All studies included in the systematic review were conducted in developed countries, which had dissimilar health system models and this may have impacted the long-term glycaemic outcomes. The study period was between years 1993 and 2012, during which period understanding of the disease and diagnostic methods for HbA1c testing improved. This may have affected the interpretation of the HbA1c measurements. Also, several changes were implemented during this period in diabetes care, practice and management, through introduction of novel fast acting insulin formulations, intensive insulin treatment and educational interventions. These and the improved diagnostic and clinic factors may have played a role in improving the overall glycaemic trajectories in the participants as reported by other studies (31, 32).

The sub-optimal HbA1c control estimated in the meta-analysis during the follow-up period may be due to more participants with higher HbA1c levels, age (33), endogenous and exogenous factors or biological variation in the glycation phenotypes of children (34-36), psychological factors particularly in older children (37, 38). These are all factors which may also have increased the risk of developing or progression of micro & macrovascular complications in those children as a consequence of those higher HbA1c levels (39).

The DCCT cohort were able to achieve HbA1c levels of 7% (53 mmol/mol) (40) as compared with 8.3% (66 mmol/mol) achieved among more than 25,000 patients from USA (41) and 8.7% (70.1 mmol/mol) achieved by the paediatric population of England

and Wales in the UK (42). This highlights the fact that, outside of a clinical trial, achieving glycaemic targets remains difficult. Hence robustly identifying factors early in the life course of childhood onset T1D that influence future glycaemic control and risk of complications remains an important clinical research goal.

Only one study provided evidence that albuminuria and retinopathy were associated with high mean HbA1c \geq 8.6% (\geq 70mmol/mol) between 3 and 15 months after diagnosis of T1D (24). This is consistent with findings by other studies, which did not meet our inclusion criteria (6, 17, 43, 44). It would be highly relevant for determining future prognosis, if these outcomes could be confirmed in future studies.

Cardiovascular disease is the major cause of death in T1D patients. Pre-symptomatic cardiovascular disease is evident in 100% of young adults with T1D (45) and there is evidence of accelerated atherosclerotic processes (46, 47) and increased severity of cardiovascular disease (48) at an earlier age compared to the general population. Landmark trials show that intensive insulin therapy reduces cardiovascular events in adults (6, 49). Although differences in HbA1c account for most of this benefit, multivariate analyses suggest that part of the reduced risk is mediated by reduction in the incidence of diabetic renal disease (50). In children and young people with T1D, atherosclerosis is present to a greater extent (51) and the prevalence of cardiovascular risk factors is greater (52, 53) than in the general population. Diabetic nephropathy incidence accelerates during adolescence (54). These are all strong indicators of a greatly elevated risk for future vascular diseases. There is currently no evidence base for the effectiveness of ACE Inhibition or statin treatments in adolescents with T1D although, the important AdDIT Trial may inform practice in the coming years (55).

Therefore currently, in order to reduce vascular complications risk, the importance of achieving good glycemic control is arguably greater in childhood compared to adult T1D populations.

The meta-analysis indicates that the overall glycaemic control stabilizes in a "track" after 6 months of childhood onset T1D diagnosis and pre-school aged children had better control throughout the follow-up period. Furthermore, the low and high HbA1c levels at baseline also seem to have metabolic memory, which shows HbA1c "tracking" during the 10-year follow-up despite differences between the high and low groups. This suggests there may be benefits of having good control during the initial few months of diagnosis. However, as these five studies report temporal associations, an experimental study of an intervention soon after diagnosis would be required to prove that better early control results in better later control. This review may also indicate a short window of opportunity to intervene and improve long-term glycaemic outcomes. It may therefore be beneficial to develop clinical and educational strategies to identify and deliver targeted interventions during this early phase to those at risk of having poor glycaemic control and to ensure that the HbA1c targets are maintained in the long-term. There is currently no evidence on effectiveness and timing of focused clinical interventions targeted at changing these tracks (18). It would be useful to gather this evidence and to explore further the mechanisms of this phenomenon in order to deliver best care to newly diagnosed children and adolescents. The findings of this review would be useful to policy makers, health professionals and T1D patients to focus on designing interventions to prevent sub-optimal glycaemic outcomes and decrease the risk of developing micro and macro vascular complications.

Strengths and limitations of the review

The many strengths of this study include, being to our knowledge, the first systematic review and meta-analysis to rigorously investigate published and unpublished literature on the association of early glycaemic control in childhood onset T1D with glycaemic tracking and future risk of complications. Furthermore, this is the first review to rigorously and systematically search and review all available evidence as per preset inclusion/exclusion and quality assessment criteria. We have taken utmost care to minimise study selection, reviewer related and publication bias. All of the included studies were intermediate to high quality.

But, there are limitations to this systematic review which need to be considered. The diabetes diagnosis, care and HbA1c outcome measures have evolved over the years and were not uniform across studies. There was considerable heterogeneity between studies. The comparable follow-up data was not available beyond 10 years. We were unable to investigate if other factors may have confounded the findings. The small number of studies and the short duration of follow-up in studies may have masked the true association with long-term glycaemic control. Although we made every effort to search for unpublished and grey literature, we may have missed some that remain unreported due to unethical practices in reporting or publication bias. The results of our study may not be generalizable as they were mainly conducted in developed countries with varied health care system models.

Review updating plans

The review will be updated if significant new evidence becomes available and results of the update review will be disseminated through peer-reviewed publications, conference presentations and at meetings.

LIST OF ABBREVIATIONS

HbA1c: Haemoglobin A1c T1D: Type 1 diabetes PROSPERO: International Prospective Register for systematic Reviews DCCT: The Diabetes Control and Complications Trial EPPI: Evidence for Policy and Practice Information RE: Random effects model FE: Fixed effects model

COMPETING INTERESTS

No potential conflict of interest was reported by the authors.

FUNDING

Funding Ref:109/0001: The Policy Research Unit in the Health of Children, Young People and Families is funded by the Department of Health and Social Care Policy Research Programme. This report is independent research commissioned and funded by the National Institute for Health Research Policy Research Programme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or its arm's length bodies, and other Government Departments. This research was supported by the National Institute for Health Research Research Biomedical Research

Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. Jessica Barrett is funded by the MRC Unit Programme (MC_UU_00002/5). David Taylor-Robinson is funded by the MRC on a Clinician Scientist Fellowship (MR/P008577/1)

AUTHORS CONTRIBUTION

VMP was the lead reviewer, designed the study, developed the study protocol, created the search strategy, searched electronic databases for literature, extracted the data, co-ordinated with authors of included studies for additional information, analysed the evidence, drafted the report and is responsible for the article. JB and DTR participated in the study design, contributed to the statistical analysis design and helped revise the manuscript. HC participated in the study design, contributed in the study design, contributed to the literature search and helped revise the manuscript. DC participated in the study design, contributed to the literature search and helped revise the manuscript. DC participated in the study design, contributed to the analyses and helped revise the manuscript. RV advised on the project, participated in the study design, commented on the analyses and helped revise the manuscript. All authors contributed to the study design, critical revision of the manuscript and approved the final version.

ACKNOWLEDGEMENTS

Our sincere thanks to Dr Mark Clements, Ms Fengming Tang, Dr Ulf Samuelsson, Dr Victoria Franklin and Dr Timothy Lawes - the authors of the included studies who provided us with clarifications and additional information for the review. We also thank the funders and colleagues from University College London especially Dr Rakesh

Amin for his initial advice on the project and help with double review of a proportion of

included papers.

REFERENCES

1. Hofer SE, Raile K, Frohlich-Reiterer E, Kapellen T, Dost A, Rosenbauer J, et al. Tracking of metabolic control from childhood to young adulthood in type 1 diabetes. J Pediatr. 2014;165(5):956-61.e1-2.

2. Edge JA, James T, Shine B. Persistent individual tracking within overall improvement in HbA1c in a UK paediatric diabetes clinic over 15 years. Diabetic medicine : a journal of the British Diabetic Association. 2010;27(11):1284-8.

3. Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, et al. Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes care. 2018;41(9):2026-44.

4. Speight J, Amiel SA, Bradley C, Heller S, Oliver L, Roberts S, et al. Long-term biomedical and psychosocial outcomes following DAFNE (Dose Adjustment For Normal Eating) structured education to promote intensive insulin therapy in adults with sub-optimally controlled Type 1 diabetes. Diabetes research and clinical practice. 2010;89(1):22-9.

5. Brorsson AL, Viklund G, Ortqvist E, Lindholm Olinder A. Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case-control study. Pediatric diabetes. 2015;16(7):546-53.

6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. The New England journal of medicine. 1993;329(14):977-86.

7. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. J Pediatr. 1994;125(2):177 - 88.

8. Harjutsalo V, Maric-Bilkan C, Forsblom C, Groop PH. Impact of sex and age at onset of diabetes on mortality from ischemic heart disease in patients with type 1 diabetes. Diabetes care. 2014;37(1):144-8.

9. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. The New England journal of medicine. 1986;315(4):215-9.

10. Helgeson VS, Siminerio L, Escobar O, Becker D. Predictors of metabolic control among adolescents with diabetes: a 4-year longitudinal study. Journal of pediatric psychology. 2009;34(3):254-70.

11. Wisting L, Froisland DH, Skrivarhaug T, Dahl-Jorgensen K, Ro O. Disturbed eating behavior and omission of insulin in adolescents receiving intensified insulin treatment: a nationwide population-based study. Diabetes care. 2013;36(11):3382-7.

12. Meigs JB, Nathan DM, Cupples LA, Wilson PW, Singer DE. Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. Journal of clinical epidemiology. 1996;49(4):411-7.

13. Hamman RF, Bell RA, Dabelea D, D'Agostino RB, Jr., Dolan L, Imperatore G, et al. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes care. 2014;37(12):3336-44.

14. Rosenbauer J, Dost A, Karges B, Hungele A, Stahl A, Bachle C, et al. Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria. Diabetes care. 2012;35(1):80-6.

15. Dovc K, Telic SS, Lusa L, Bratanic N, Zerjav-Tansek M, Kotnik P, et al. Improved metabolic control in pediatric patients with type 1 diabetes: a nationwide prospective 12-year time trends analysis. Diabetes technology & therapeutics. 2014;16(1):33-40.

16. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007;50(11):2239-44.

17. Svensson M, Eriksson JW, Dahlquist G. Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden. Diabetes care. 2004;27(4):955-62.

18. Nirantharakumar K, Mohammed N, Toulis KA, Thomas GN, Narendran P. Clinically meaningful and lasting HbA1c improvement rarely occurs after 5 years of type 1 diabetes: an argument for early, targeted and aggressive intervention following diagnosis. Diabetologia. 2018.

19. Mazarello Paes V, Charalampopoulos D, Khanolkar A, Taylor-Robinson D, Viner R, Edge J, et al. Protocol for systematic review of evidence on the determinants and influence of early glycaemic control in childhood-onset type 1 diabetes. Systematic Reviews. 2015;4(1):159.

20. EPPI. Evidence for Policy and Practice Information (EPPI) and Co-ordinating Centre, IoE, University of London. EPPI -Centre Methods for Conducting Systematic Reviews. http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=184 last accessed 15/09/2018. 2018.

21. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.

22. Watson PF, Petrie A. Method agreement analysis: a review of correct methodology. Theriogenology. 2010;73(9):1167-79.

23. Higgins JP, Green S, editors: Cochrane handbook for systematic review of interventions, Chichester: Wiley-Blackwell; 2008.

24. Samuelsson U, Steineck I, Gubbjornsdottir S. A high mean-HbA1c value 3-15 months after diagnosis of type 1 diabetes in childhood is related to metabolic control, macroalbuminuria, and retinopathy in early adulthood--a pilot study using two nation-wide population based quality registries. Pediatric diabetes. 2014;15(3):229-35.

25. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Statistics in medicine. 2008;27(5):625-50.

26. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539-58.

27. Lawes T, Franklin V, Farmer G. HbA1c tracking and bio-psychosocial determinants of glycaemic control in children and adolescents with type 1 diabetes: retrospective cohort study and multilevel analysis. Pediatric diabetes. 2014;15(5):372 - 83.

28. Shalitin S, Phillip M. Which factors predict glycemic control in children diagnosed with type 1 diabetes before 6.5 years of age? Acta diabetologica. 2012;49(5):355-62.

29. Clements MA, Lind M, Raman S, Patton SR, Lipska KJ, Fridlington AG, et al. Age at diagnosis predicts deterioration in glycaemic control among children and adolescents with type 1 diabetes. BMJ open diabetes research & care. 2014;2(1):e000039.

30. Cabrera SM, Srivastava NT, Behzadi JM, Pottorff TM, Dimeglio LA, Walvoord EC. Long-term glycemic control as a result of initial education for children with new onset type 1 diabetes: does the setting matter? The Diabetes educator. 2013;39(2):187-94.

31. de Beaufort CE, Swift PG, Skinner CT, Aanstoot HJ, Aman J, Cameron F, et al. Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere Study Group on Childhood Diabetes. Diabetes care. 2007;30(9):2245-50.

32. Svensson J, Johannesen J, Mortensen HB, Nordly S. Improved metabolic outcome in a Danish diabetic paediatric population aged 0-18 yr: results from a nationwide continuous Registration. Pediatric diabetes. 2009;10(7):461-7.

33. Dabadghao P, Vidmar S, Cameron FJ. Deteriorating diabetic control through adolescence-do the origins lie in childhood? Diabetic medicine : a journal of the British Diabetic Association. 2001;18(11):889-94.

34. Yudkin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ. Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia. 1990;33(4):208-15.

35. Kilpatrick ES, Rigby AS, Atkin SL. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clinical chemistry. 2007;53(5):897-901.

36. Hempe JM, Gomez R, McCarter RJ, Jr., Chalew SA. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. Journal of diabetes and its complications. 2002;16(5):313-20.

37. Luyckx K, Seiffge-Krenke I. Continuity and change in glycemic control trajectories from adolescence to emerging adulthood: relationships with family climate and self-concept in type 1 diabetes. Diabetes care. 2009;32(5):797-801.

38. Bryden KS, Dunger DB, Mayou RA, Peveler RC, Neil HA. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes care. 2003;26(4):1052-7.

39. Nathan D, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin J. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30years: advances and contributions. Diabetes. 2013;62(12):3976 - 86.

40. Ali M, Bullard K, Saaddine J, Cowie C, Imperatore G, Gregg E. Achievement of goals in U.S. diabetes care, 1999-2010. The New England journal of medicine. 2013;368(17):1613 - 24.

41. Beck R, Tamborlane W, Bergenstal R, Miller K, DuBose S, Hall C. The T1D exchange clinic registry. J Clin Endocrinol Metab. 2012;97(12):4383 - 9.

42. RCPCH. National Paediatric Diabetes Audit Report 2014-15. Care processes and outcomes 2016. Available from:

http://www.rcpch.ac.uk/sites/default/files/page/NPDA%20Report%202014-15%20v5.2%20sent%20to%20HQIP%2025.05.2016.pdf.

43. Olsen BS, Sjolie AK, Hougaard P, Johannesen J, Marinelli K, Jacobsen BB, et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. Journal of diabetes and its complications. 2004;18(3):160-4.

44. Fredheim S, Johannesen J, Johansen A, Lyngsoe L, Rida H, Andersen ML, et al. Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia. 2013;56(5):995-1003.

45. Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes. 2002;51(8):2637-41.

46. Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, et al. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes. 2003;52(11):2833-9.

47. Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, van Staa T, et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital

care, disease registry, and national mortality records: cohort study. BMJ (Clinical research ed. 2013;346:f2350.

48. Pajunen P, Taskinen MR, Nieminen MS, Syvanne M. Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. The American journal of cardiology. 2000;86(10):1080-5.

49. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. The New England journal of medicine. 2003;348(23):2294-303.

50. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England journal of medicine. 2005;353(25):2643-53.

51. Dahl-Jorgensen K, Larsen JR, Hanssen KF. Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment? Diabetologia. 2005;48(8):1445-53.

52. Giannattasio C, Failla M, Piperno A, Grappiolo A, Gamba P, Paleari F, et al. Early impairment of large artery structure and function in type I diabetes mellitus. Diabetologia. 1999;42(8):987-94.

53. Schwab KO, Doerfer J, Hecker W, Grulich-Henn J, Wiemann D, Kordonouri O, et al. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes care. 2006;29(2):218-25.

54. Amin R, Frystyk J, Ong K, Dalton RN, Flyvbjerg A, Dunger DB. The development of microalbuminuria is associated with raised longitudinal adiponectin levels in female but not male adolescent patients with type 1 diabetes. Diabetologia. 2008;51(9):1707-13.

55. Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT). BMC pediatrics. 2009;9(1):1-18.

No Author, year, country and study period	Study design and data source	Population	Age range of study population	Follow- up period	Treatment	Outcome and measure	Definition of early HbA1c	Statistical Analyses	Association	Quality score (max 6) and comments
1 Samuelsson 2014 Sweden 2000 - 2010	Retrospectiv e/Prospectiv e pilot study National databases (paediatric plus adult) Swedish paediatric diabetes quality registry (SWEDIABKID S) and the national diabetes register (NDR). Mean visits in SWE: 19.5 Mean visits in NDR: 4 Mean age in SWE: 13.9±2.5 years Mean age in NDR: 21.0±2.3 years	Generalizability: Non rep Sample size: 1543 children and adolescents. Males: 920 Ethnicity: NR SES:NR Family history of T1D:NR 5-9 yr olds: N= 89 (5.8%) 10-14 yr olds: N= 769 (49.8%) 15-19 yr olds: N= 685 (44.4%) Mean HbA1c adjacent to diagnosis: 8.6% (\geq 70mmol/mol) Mean HbA1c months 3-15 in relation to age at diagnosis: 5-9 yr olds: 7.5% ± 1.1 (58.7 ± 12) 10-14 yr olds: 7.2%	5-19 years Mean age at diagnosis: 13.9 ± 2.5 years.	1-12 years Mean: 7.1 ±2.5 years	NR	Metabolic control (HbA1c) and detection of albuminuria, retinopathy in early adulthood Standardised assay for HbA1c. Urine albumin excretion. Physical activity levels	HbA1c values between 3 and 1 15 months after diagnosis	1) MVLR: Mean HbA1c in NDR (dependent) and Mean HbA1c months 3-15 after diagnosis (independent: a) Unadjusted: R-square 0.159, Beta Coefficient 0.466; 95% CI (0.408 – 0.525); t=15.6; p=0.001 b) Adjusted (for age at diagnosis, gender, duration of diabetes, smoking PA): R-square 0.206, Beta Coefficient 0.414; 95% CI (0.355 – 0.473); t=13.2; p=0.001 2) LR unadjusted OR with 95% CI a) HbA1c group 6.8 – 8.6% (51- 69mmol/mol); Ref ≤ 6.7% (≤50mmol/mol): i) Macroalbuminuria: 1.3 (0.3 - 6.0) ii) Microalbuminuria: 0.9 (0.5 - 1.4) iii) Retinopathy: 1.6 (1.2 – 2.1); p<0.01 b) HbA1c group ≥ 8.7% (≥70 mmol/mol); Ref ≤6.7% (≤50mmol/mol): i) Macroalbuminuria: 2.0 (1.1 - 3.8), p<0.05 iii) Retinopathy: 2.6 (1.7 – 3.8); p<0.01 3) LR adjusted (gender, duration of T1D, age at diagnosis, PA and smoking) OR with 95% CI	 ++ Children with poor metabolic control adjacent to diagnosis had higher HbA1c levels in adulthood. ++ micro and macroalbuminuria and retinopathy in early adults seen in patients with high mean HbA1c during 3-15 mo post diagnosis. ++ HbA1c levels higher in young children as compared to pubertal children (12 y for girls and 14 y for boys) + girls had higher HbA1c levels + PA levels lower in patients with high HbA1c levels, micro/macro albuminuria and retinopathy +Smoking observed in patients with high HbA1c levels, micro/macro albuminuria and retinopathy 	High (5) non- representati ve child population. Children < 5 years not included

Table 1: Description of longitudinal studies investigating the impact of early glycaemic control on long-term HbA1c and risk of complications in childhood onset T1D

			15-19 yr olds: 7.04% ± 1.3 (50.5 ± 14)						a) HbA1c group $6.8 - 8.6\%$ (51- $69mmol/mol$); Ref $\leq 6.7\%$ ($\leq 50mmol/mol$): i) Macroalbuminuria: 0.6 (0.1 - 6.9) ii) Microalbuminuria: 0.9 (0.6 -1.7) iii) Retinopathy: 1.4 (1.1 - 1.9); p<0.05 b) HbA1c group $\geq 8.7\%$ (≥ 70 mmol/mol); Ref $\leq 6.7\%$ $\leq 50mmol/mol$): i) Macroalbuminuria: 14.3 (2.6 - 78.2); $p<0.01ii) Microalbuminuria: 1.7 (0.8 -3.4)iii) Retinopathy: 2.0 (1.2 - 3.1);p<0.01$		
2	Clements	Prospective	Generalizability:	0-20 years	5 years	Stratified	1)Associatio	HbA1c during	Mean (SD) 1st HbA1c after 3months	++ Significant increase in HbA1c levels	High (5)
	2014	cohort	Rep			by	n with	first 3 months	of diagnosis 7.7 ± 1.9 (60.7 ±20.8	by increasing age of diagnosis with ≥10	
				Mean age		diagnostic	HbA1c levels	of diagnosis	mmol/mol)	year olds experiencing poorer	5 different
	USA	The	Sample size: 2218	at		era which	at diagnosis,	and/or 4 – 12	V/S	glycaemic control. Younger patients	methods
	1000 0000	Children's	children and	diagnosis:		included	1.5 and 5	months after	mean HbA1c in the 5th year after	had better control across all HbA1c sub	used to
	1993 - 2009	Mercy	adolescents.	9.0 ±4.1		the	year f/u by	diagnosis	diagnosis 9.2 ± 1.8 (106.6 ±28.0	categories p<0.001	analyse
		Hospital Type 1 diabetes in	Males: 1166	years		following regimen as	diagnostic	Three groups	mmol/mol)	The group with HbA1c <7 has steeper	HbA1c during the
		paediatrics	wates. 1100			first line	age, ethnicity,	of patients	Comparison of mean 1st HbA1c	increase for the first 1.5 years.	study period
		database,	Ethnicity: 86.1%			therapy	and	based on	after 3months of diagnosis V/S	However, it seems all three groups	study period
		USA.	non-Hispanic			therapy	diagnostic	baseline	mean HbA1c in the 5th year after	ended at about the same level at 5	
			Caucasian, 8.9%			Pre 2000:	era	HbA1c: a) <7,	diagnosis by HbA1c tertiles < 7, 7-9	years except for the patients who were	
			non-Hispanic			Split		b) 7 to 9, c)	and > 9 % (< 53, 53 -75 and >75	diagnosed at >10 years old of the	
			African-American,			regimen	Various	>9.	mmol/mol)	HbA1c >9 group.	
	1		5% other or			dosing	methods				
			Hispanic),				used to		(1) HbA1c in children with < 7: mean	++ 0-4 year old did not show much	
						2000-	measure		6.2 ± 0.5 (n = 871) v/s 9.1 ± 1.8 (n =	change in HbA1c trajectory over 5	
			SES:NR			2003:	HbA1c		609 missing)	years, but progressive increase in	
			Family history of			multiple daily	during the study period		(2) HbA1c 7 – 9: mean 7.9 ± 0.6 (n = 940) v/s 9.1 ± 1.5 (n=483 missing)	HbA1c levels in all age groups, highest in >10 year olds (p<0.001).	
	1		T1D:NR			injections	i.e. HPLC,		(3) HbA1c > 9: mean 10.7 \pm 1.8 (n =	Highest HbA1c inflection point is at	
						injections	Boronate		(3) (100 \times 200 \times	around 1.5 years post diagnosis	
	1					2004-	affinity.				
						2009:	-,		Regression, stratified analyses	++ Small but statistically significant	
						Continuou	2) Effect of			differences within gender subgroups	
						s	insulin		Effect of insulin therapy:	across diagnostic age groups	
						subcutane	therapy on		Children with <7% (53mmol/mol) at	(p<0.0001).	
						ous insulin	HbA1c		diagnosis had higher HbA1c levels		
						infusion	tertiles i.e.				

							Children with <7% (<53mmol/m ol), 7-9% (53- 75mmol/mol) and >9% (>75%)		during 1.5 years after diagnosis across all age groups. Overall HbA1c levels rose yearly by 1.83% (1.72 to 1.94) (20.0 mmol/mol (18.8 to 20.2). HbA1c rise was less steep but significant in children with baseline HbA1c between 7% (53mmol/mol) and 9% (75mmol/mol) (0.81% (0.69 to 0.92) (8.9 mmol/mol) (0.81% (0.69 to 0.92) (8.9 mmol/mol) (7.5 to 10.1))). Patients with baseline HbA1c >9% (75mmol/mol) had stable or improved control at 1.5 years post diagnosis with an overall yearly decline of -0.68% (-0.87 to -0.49) per year (-7.4 mmol/mol (-9.5 to -5.3) Non- Hispanic black v/s non- Hispanic white mean (SD): 10.2% (±2.5) (88.0 ±27.3 mmol/mol) and 8.4% (±1.4) (68.0 ±15.3 mmol/mol) Pre 2000 era mean (SD): 8.9% (±1.5) (73.8 ±16.4 mmol/mol) 2000-2003 mean (SD): 8.7% (±1.6) (71.6 ±17.5 mmol/mol) 2004-2009 mean (SD): 8.1% (±1.7) (65.0 ±18.6 mmol/mol)	++ HbA1c levels were higher in non- Hispanic black patients (p value for race/ethnicity x age interaction <0.001 Also rate of HbA1c levels rise during 1.5 years post diagnosis was greater in non- Hispanic black patients in each age sub group. ++ high levels in pre 2004-2009 group at diagnosis, 1.5 and 5 years p<0.001.	
3	Lawes 2014 North of Scotland, UK Jan 1993 – Aug 2012	Retrospectiv e cohort Regional database (paediatric) from NHS Highland Paediatric diabetic services, North of Scotland,	Generalizability: Non rep Sample size: 155 children ≤ 16 years. Males: n= 74. Ethnicity: limited ethnic diversity SES and family history of T1D:	0-16 years Median baseline age: 7.9 (range 4.5 to 10.9 years).	Up to 15 years Media n f/u: 4 years 10 month s	Lower use of intensive insulin (basal bolus) regimens. No patients on pump therapy.	HbA1c trends and association with 6 month HbA1c Bayer DCA 2000 near- patient analyser	Baseline HbA1c defined as HbA1c at or nearest to 6 months from diagnosis	LMR: 0.9% (10mmol/mol) increase at 6 month HbA1c was associated with 0.5% (0.4-0.6%) or 5.3mmol/mol (4.5-6.2) increase at all subsequent time points (95% CI: p<0.001) A 2.4% (1.1 to 3.6%) or 26 mmol/mol (12 to 39) increase in HbA1c was seen at 10 year f/u in patients from highest 6 months HbA1c quintile (8.6 vs 6.2% or 94 vs 68mmol/mol) p<0.001	++ Significant mean HbA1c levels and shape of trajectories after adjusting for patient and observation level predictors. ++A higher 6 month HbA1c was associated with slow but sustained HbA1c deterioration with T1D duration as compared to lower 6 month HbA1c Time independent variables significantly associated with poorer glycaemic control were age at	Intermediate (4) Retrospectiv e study design. Non- rep - excluded patients with < 1 year f/u from diagnosis. Included only patients

			study reports as nationally comparable 40% patients lived in remote/rural areas.				3121 HbA1c measuremen ts		Cross-correlation coefficients for 6- months HbA1c on linear and quadratic growth identified sustained effects on trajectories of glycaemic control (p<0.001)	diagnosis, living with <2 biological parents, proximity to urban clinic, neighbourhood deprivation, child with welfare concerns and with thyroid disease. Time dependent covariates: mental health problems, major adverse life events, clinic non- attendance, lower BMI SDS (particularly in girls), were associated with higher HbA1c levels.	from North Scotland. Attrition rate was high (approx. 80%) at 10 year f/u
4	Shalitin 2012 Israel Jan 1999 – May 2009	Retrospectiv e cohort Diabetes clinic database within a tertiary hospital - the National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel.	Generalizability: Non rep Sample size: 173 pre-school aged children 0.5 to 6.5 years Males = 84 Ethnicity: Jews=84.4%, Arabs=12.1% and Ethiopian Jews=3.5% SES: only parental marital status reported Family history of T1D: NR Mean duration of diabetes: 4.9 ±2.8 years or median 4.3 (range 1 – 11 years)	0.5 – 17 years Mean age at diagnosis: 3.8 ± 1.6 years	0 – 7 years	All patients were advised on carbohydr ate counting, required to perform self- blood glucose measurem ents at least 6 times/day and several different types of insulin regimen (multiple daily injections or continuou s subcutane ous insulin infusion) were used.	HbA1c trends (in patients with <7.5% (n=53) and ≥7.5% (n=120) HbA1c) and association with HbA1c at onset Capillary HbA1c measured every 3 months by automated immunoche mical technique using Bayer DCA 2000; reference range 4.3 – 5.8%. During f/u: HbA1c <7.5% : n=53 (30.6% patients) HbA1c ≥7.5% : n=120	HbA1c at T1D onset	MLRA: OR=0.44; 95% Cl0.26-0.72; p=0.002 and OR=0.09; 95% Cl 0.04- 0.24; P<0.001 for every 1% increase in HbA1c at 0.5 and 1 year after T1D onset. HbA1c in patients with <7.5% : At onset: 9.5 \pm 2.1 (n=53) At 0.5 years after onset: 6.8 \pm 0.9 (n=53) At 1 years after onset: 7.0 \pm 0.6 (n=53) At 2 years after onset: 7.1 \pm 0.5 (n=42) At 3 years after onset: 7.1 \pm 0.5 (n=26) At 4 years after onset: 7.2 \pm 0.6 (n=26) At 5 years after onset: 6.8 \pm 0.5 (n=14) At 6 years after onset: 6.8 \pm 0.3 (n=11) At 7 years after onset: 6.9 \pm 0.3 (n=4) HbA1c at last visit: 7.3 \pm 0.7 HbA1c in patients with >7.5% : At onset: 10.2 \pm 1.8 (n=120) At 1 years after onset: 8.3 \pm 1.2 (n=120) At 2 years after onset: 8.4 \pm 0.9 (n=120) At 2 years after onset: 8.3 \pm 0.8 (n=98)	 ++ Lower HbA1c values at 0.5 and 1 year after T1D onset, predicted achievement of HbA1c target of <7.5%. ++ comparison of HbA1c between below target and above <7.5% target in patients was significant ++ Patients with celiac disease (n=21) had lower mean HbA1c compared to those without (n=152). 7.5 ±0.8% vs 8.0 ±0.8%, p=0.01 + children from single parent family and those with more DKA events had higher HbA1c levels, but this was not statistically significant There were no statistically significant differences between groups in Gender, ethnicity, age at diagnosis, presence of DKA at onset, mean number of SBGM and insulin regimen type (MDI or CSSII). 	Intermediat e (3) retrospectiv e study design; non- representati ve child population. Children < 0.5 years and >6.5 years at baseline not included, analyses. Attrition rate was 62, 66 and 73% at 5, 6 and 7 year f/u respectively.

							(69.4%		At 3 years after onset: 8.4 ±0.8		
							patients)		(n=79) At 4 years after onset: 8.4 ±0.8		
							Attrition rate		(n=68) (n=68)		
							was 62, 66		At 5 years after onset: 8.4 ±0.9		
							and 73% at		(n=57)		
							5, 6 and 7		At 6 years after onset: 8.4 ±0.9		
							year f/u		(n=47)		
							respectively.		At 7 years after onset: 8.3 ±1.0		
									(n=42)		
									HbA1c at last visit:8.4±1.0		
5	Cabrera	Retrospectiv	Generalizability:	1.1 - 13.9	0-5	Patients	HbA1c levels	HbA1c at T1D	Mean (SE): At diagnosis: 9.53(0.24)	The A1C was also highly consistent in	Intermediate
	2013	e cohort	Rep	years	years	with initial	at 0, 2, 3 and	onset		each patient over time.	(4)
			Sample size: 138			T1D	5 years after		GEE Mean(SE): at 2 years: 8.81(0.09)	/ Long-term glycaemic control was	retrospectiv
	USA	Electronic	children 1.1 – 13.9	Mean age		education	diagnosis in		at 3 years:8.94(0.12)	independent of whether initial	e study
		clinical	year old	at		from	AMC v/s non		at 5 years: 8.84(0.12)	education was delivered at an AMC or	design;
	1998 –2002	database of	NA -1 74	diagnosis:		academic	AMC			non-AMC.	analyses.
		the Section of Pediatric	Males = 71	6.8 ± 3.3		medical	referred patients.		Correlations of A1C values over time for all individual patients	/ Formal education and location at time of diagnosis do not appear to play	Attrition rate
		Endocrinolog	Ethnicity:	years		center (AMC) V/S	patients.		(p<0.001)	a significant role in long-term	Attrition rate appears to
		y/Diabetolog	white=91.5%,			non-AMC			Change from 2 to 3 years $(n=130)$:	glycaemic control.	be 8 at 2 and
		y at Riley	other=8.5%			patients	Initial A1C by		0.648	giveaenie control.	3 years
		Hospital for				patiento	either by		Change from 2 to 5 years (n=130):		o years
		Children,	SES: parental			Insulin	Bayer		0.524		
		Indiana, USA	marital status and			therapy:	DCA2000 or		Change from 3 to 5 years (n=138):		
			insurance type			NR	by HPLC at		0.520		
			reported				the central				
							lab. All				
			Family history of				patients				
			T1D : NR				subsequentl				
							y had their				
			Mean duration of				A1C				
			diabetes: 5 years				determined by the Bayer				
							DCA2000 at				
							follow-up				
							clinic visits.				
							A1C levels				
							were				
							obtained				
							from the				
							records of				
							subsequent				
							clinic visits,				
							and mean				

			A1C was			
			calculated			
			for years 2,			
			3, and 5			
			from date of			
			diagnosis.			

T1D: Type 1 diabetes; NON REP: Non representative of general population; SD: standard deviation; BMI SDS: Body mass index standard deviation score; PA: physical activity; MVLR: Multivariate linear regression; LMR: linear multilevel regression; MLRA: Multiple logistic regression Analysis; GEE: Generalised estimating equation; CI: confidence intervals; LR: logistic regression; OR: Odds ratio; ++: statistically significant positive association; + or -: statistically non- significant positive or negative association

	MA with all 4 stu	dies		Sensitivity MA (after excluding study in pre-school children)					
T1D duration	SMD (95% CI)	HbA1c % (95% Cl)	Heterogeneity (I ²)	SMD (95% CI)	HbA1c % (95% Cl)	Heterogeneity (I ²)			
after 6 months of T1D diagnosis	-1.25 (-1.53, -0.97)	-2.28% (-2.79%, -1.77%)	0.0%, p=0.41	-1.10 (-1.56, -0.65)	-2.37% (-3.35%, -1.40%)	0.0%, p=0.01			
after 1 year of T1D diagnosis	-0.85 (-0.95, -0.75)	-2.02% (-3.06%, -0.97%)	91.0%, p=0.001	-0.79 (-0.89, -0.69)	-1.74% (-1.96%, -1.52%)	0.0%, p=0.61			
after 2 years of T1D diagnosis	-0.84 (-0.95, -0.74)	-1.76% (-2.63%, -0.90%)	87.8%, p=0.001	-0.78 (-0.89, -0.67)	-1.48% (-1.69%, -1.27%)	0.0%, p=0.73			
after 3 years of T1D diagnosis	-0.78 (-0.89, -0.66)	-1.75% (-2.80%, -0.70%)	90.5%, p=0.001	-0.71 (-0.83, -0.59)	-1.48% (-1.73%, -1.23%)	0.0%, p=0.93			
after 5 years of T1D diagnosis	-0.44 (-0.54, -0.34)	-1.25% (-2.03%, -0.48%)	90.9%, p=0.001	-0.41 (-0.73, -0.09)	-0.90% (-1.60%, -0.20%)	85.7%, p=0.001			
after 7 years of T1D diagnosis	-0.75 (-0.94, -0.55)	-1.19% (-1.62%, -0.74%)	16.6%, p=0.30	-0.72 (-0.92, -0.53)	-1.48% (-1.89%, -1.09%)	0.0%, p=0.40			
after 10 years of T1D diagnosis	-0.32 (-0.63, -0.02)	-0.95% (-1.87%, -0.06%)	0.0%, p=0.67	-0.32 (-0.63, -0.02)	-0.95% (-1.87%, -0.06%)	0.0%, p=0.67			

Table 2: Summary of pooled standardised mean differences in HbA1c levels between low and high HbA1c groups

MA: Meta-analysis; SMD: standardised mean difference, T1D: Type 1 diabetes; HbA1c: Glycated Haemoglobin




Figure 2: Summary of FE & RE models: Pooled estimates of overall glycaemic control at follow-up

Study	Country	Study_Period	Age_at_diagnosis	N		ES (95% CI)	(I-V)
HbA1c at T1D diag	nosis						
Shalitin 2012	Israel	1999 -2009	3.8±1.6	173	•	9.85 (9.56, 10.14)	11.6
Cabrera 2013	USA	1998-2002	6.8±3.3	138	▲	9.53 (9.06, 10.00)	4.44
Clements 2014	USA	1993-2009	9.0±4.1	2218	· · · · ·	11.90 (11.79, 12.01)	83.9
-V Subtotal (I-squa	ared = 99.2%, p =					11.56 (11.46, 11.66)	100.
D+L Subtotal		,				10.44 (8.75, 12.12)	
HbA1c after 3 mont	ths of T1D diagno	sis					
Clements 2014	USA	1993-2009	9.0±4.1	2218		7.70 (7.62, 7.78)	61.4
Samuelsson 2014	Sweden	2000-2010	13.9±2.5	1543		7.80 (7.70, 7.90)	38.5
-V Subtotal (I-squa		0.124)			Ĩ	7.74 (7.68, 7.80)	100
D+L Subtotal	,	·····,			•	7.75 (7.65, 7.84)	
HbA1c after 6 mont	ths						
Shalitin 2012	Israel	1999-2009	3.8±1.6	173	•	7.55 (7.39, 7.71)	86.4
.awes 2014	Scotland, UK	1993-2012	7.8±3.4	114		8.00 (7.61, 8.39)	13.
-V Subtotal (I-squa		0.038)			· · · · · · · · · · · · · · · · · · ·	7.61 (7.47, 7.76)	100
D+L Subtotal		,			Ö	7.74 (7.30, 8.17)	
HbA1c after 1 year							
Shalitin 2012	Israel	1999-2009	3.8±1.6	173	•	7.70 (7.59, 7.81)	46.8
awes 2014	Scotland, UK	1993-2012	7.8±3.4	114	▲	8.15 (7.74, 8.56)	3.4
Samuelsson 2014	Sweden	2000-2010	13.9±2.5	1511	l l	7.85 (7.74, 7.96)	49.
-V Subtotal (I-squa	ared = 69.6%, p =				T	7.79 (7.71, 7.87)	100
)+L Subtotal					÷	7.82 (7.66, 7.99)	
IbA1c after 2 years	5						
Shalitin 2012	Israel	1999-2009	3.8±1.6	140		7.70 (7.59, 7.81)	51.
Cabrera 2013	USA	1998-2002	6.8±3.3	122	· · · · · · · · · · · · · · · · · · ·	8.81 (8.55, 9.07)	9.0
awes 2014	Scotland, UK	1993-2012	7.8±3.4	114	▲	8.65 (8.32, 8.98)	5.4
Samuelsson 2014	Sweden	2000-2010	13.9±2.5	1331		7.85 (7.72, 7.98)	34.
-V Subtotal (I-squa						7.90 (7.83, 7.98)	100
D+L Subtotal					`	8.23 (7.78, 8.69)	
HbA1c after 3 years	5						
Shalitin 2012	Israel	1999-2009	3.8±1.6	116		7.75 (7.63, 7.87)	48.
Cabrera 2013	USA	1998-2002	6.8±3.3	138	· · · · · · · · · · · · · · · · · · ·	8.94 (8.63, 9.25)	6.8
Samuelsson 2014	Sweden	2000-2010	13.9±2.5	1120		7.90 (7.77, 8.03)	40.
awes 2014	Scotland, UK	1993-2012	7.8±3.4	114	~	8.95 (8.56, 9.34)	4.3
-V Subtotal (I-squa						7.94 (7.86, 8.03)	100
D+L Subtotal	100 - 5010 /0, p -	0.000)			`	8.35 (7.88, 8.82)	
IbA1c after 5 years							
Shalitin 2012	Israel	1999-2009	3.8±1.6	71	-	7.60 (7.44, 7.76)	24.
abrera 2013	USA	1998-2002	6.8±3.3	138		8.84 (8.50, 9.18)	5.7
lements 2014	USA	1993-2009	9.0±4.1	925		9.20 (9.08, 9.32)	47.
amuelsson 2014	Sweden	2000-2010	13.9±2.5	925 772		8.10 (7.92, 8.28)	19.
awes 2014	Scotland, UK	1993-2012	7.8±3.4	80	▼_	9.25 (8.72, 9.78)	2.3
-Wes 2014 -V Subtotal (I-squa			1.013.4				100
-v Subtotal (I-squa)+L Subtotal	aieu - 30.0%, p =	0.000)			\$	8.57 (8.49, 8.65) 8.59 (7.84, 9.33)	100
IbA1c after 7 years							
Shalitin 2012	s Israel	1999-2009	3.8±1.6	46		7.60 (7.41, 7.79)	50.
Samuelsson 2014	Sweden	2000-2010	13.9±2.5	465		8.20 (8.00, 8.40)	50. 42.
awes 2014				405 58		9.30 (8.82, 9.78)	
	Scotland, UK	1993-2012	7.8±3.4	50			7.7
-V Subtotal (I-squa)+L Subtotal	area - 90.0%, p =	0.000)				7.99 (7.85, 8.12) 8.33 (7.60, 9.06)	100
lbA1c after 10 yea					, , , , , , , , , , , , , , , , , , ,		
ibA1c atter 10 yea Samuelsson 2014	rs Sweden	2000-2010	13.9±2.5	193		8.55 (8.18, 8.92)	92.
awes 2014	Scotland, UK	1993-2012	7.8±3.4	25		9.10 (7.79, 10.41)	7.2
-V Subtotal (I-squa	•					8.59 (8.24, 8.94)	100
)+L Subtotal					ŏ	8.59 (8.24, 8.94)	100

FE: fixed effects; RE: random effects; N: number of participants; ES: pooled estimates of HbA1c in absolute units at various time points; I-V: inverse variance; D+L: DerSimonian and Laird

Figure 3: Summary of FE & RE models: Estimated SMD of HbA1c levels with 95% CI between the low (exposed to glycaemic control) and high (unexposed to glycaemic control) HbA1c groups during various time-points of follow-up

Study Co	untry	Age_at_diagnosis	SMD (95% CI)	N, mean (SD); HbA1c <7%	N, mean (SD); HbA1c >7%	% Weight (I-V)	Mean_HbA
HbA1c after 6 months							
Lawes 2014 Sco	otland, UK	7.8±3.4	-1.10 (-1.56, -0.65)	27, 6.8 (2.1)	87, 9.2 (2.2)	37.57	8
Shalitin 2012 Isra	ael	3.8±1.6	-1.34 (-1.70, -0.99)	53, 6.8 (.9)	120, 8.3 (1.2)	62.43	7.55
I-V Subtotal (I-square	d = 0.0%,	p = 0.414)	-1.25 (-1.53, -0.97)		207	100.00	
D+L Subtotal		\diamond	-1.25 (-1.53, -0.97)				
HbA1c after 1 year							
Lawes 2014 Sco	otland, UK	7.8±3.4	-0.90 (-1.35, -0.45)	27, 7.1 (2.1)	87, 9.2 (2.4)	4.89	8.15
Samuelsson 2014 Sw	eden	13.9±2.5 🔶	-0.78 (-0.89, -0.68)	655, 7 (2)	856, 8.7 (2.3)	87.97	7.85
Shalitin 2012 Isra	ael	3.8±1.6	-1.71 (-2.08, -1.34)	53, 7 (.6)	120, 8.4 (.9)	7.14	7.7
I-V Subtotal (I-square	d = 91.0%	, p = 0.000) 🔷	-0.85 (-0.95, -0.75)	735	1063	100.00	
D+L Subtotal		\diamond	-1.12 (-1.70, -0.54)				
HbA1c after 2 years							
Lawes 2014 Sco	otland, UK	7.8±3.4	-0.86 (-1.31, -0.41)	27, 7.8 (1.5)	87, 9.5 (2.1)	5.65	8.65
Samuelsson 2014 Sw	eden	13.9±2.5	-0.78 (-0.89, -0.67)	543, 6.9 (2.5)	788, 8.8 (2.4)	87.69	7.85
Shalitin 2012 Isra	ael	3.8±1.6	-1.66 (-2.07, -1.25)	42, 7.1 (.5)	98, 8.3 (.8)	6.66	7.7
I-V Subtotal (I-square	d = 87.8%	, p = 0.000)	-0.84 (-0.95, -0.74)	612	973	100.00	
D+L Subtotal		\diamond	-1.08 (-1.61, -0.55)				
HbA1c after 3 years							
Lawes 2014 Sco	otland, UK	7.8±3.4	-0.69 (-1.13, -0.25)	27, 8.2 (2.1)	87, 9.7 (2.2)	6.83	8.95
Samuelsson 2014 Sw	eden	13.9±2.5	-0.71 (-0.83, -0.59)	435, 7.1 (2)	685, 8.7 (2.4)	86.77	7.9
Shalitin 2012 Isra	ael	3.8±1.6	-1.81 (-2.26, -1.35)	37, 7.1 (.5)	79, 8.4 (.8)	6.40	7.75
I-V Subtotal (I-square	d = 90.5%	, p = 0.000)	-0.78 (-0.89, -0.66)	499	851	100.00	
D+L Subtotal		\diamond	-1.05 (-1.68, -0.42)				
HbA1c after 5 years							
Clements 2014 US		9.0±4.1	-0.22 (-0.37, -0.08)		663, 9.5 (1.8)	50.15	9.2
	otland, UK	•	-0.38 (-0.88, 0.12)		59, 9.7 (2.3)	4.10	9.25
Samuelsson 2014 Sw		13.9±2.5	-0.62 (-0.78, -0.47)		523, 8.9 (2.6)	43.43	8.1
Shalitin 2012 Isra		3.8±1.6	-1.91 (-2.57, -1.24)		57, 8.4 (.9)	2.33	7.6
-V Subtotal (I-square	d = 90.9%	, p = 0.000)	-0.44 (-0.54, -0.34)		1302	100.00	
D+L Subtotal		\diamond	-0.67 (-1.09, -0.26)				
HbA1c after 7 years							
	otland, UK		-0.49 (-1.07, 0.08)		41, 9.8 (2.2)	11.67	9.3
Samuelsson 2014 Sw		13.9±2.5	-0.76 (-0.97, -0.54)		343, 9.1 (2.5)	84.98	8.2
Shalitin 2012 Isra		3.8±1.6	-1.45 (-2.51, -0.38)		42, 8.3 (1)	3.35	7.6
I-V Subtotal (I-square	a = 16.6%	, p = 0.302) 🔀	-0.75 (-0.94, -0.55)		426	100.00	
D+L Subtotal		\sim	-0.75 (-1.02, -0.47)				
HbA1c after 10 years		- 010 4				44.45	
	otland, UK	(.813.4	-0.14 (-1.06, 0.78)		19, 9.3 (2.4)	11.18	9.1
Samuelsson 2014 Sw		13.9±2.5	-0.35 (-0.67, -0.02)		144, 9 (2.6)	88.82	8.55
-V Subtotal (I-square	a = 0.0%,	13.9±2.5 p = 0.674)	-0.32 (-0.63, -0.02)		163	100.00	
D+L Subtotal		\diamond	-0.32 (-0.63, -0.02)				
		-2.57 (2.57				

SMD: standardised mean difference; CI: confidence interval; N: number of participants; SD: standard deviation; I-V: inverse variance; D+L: DerSimonian and Laird

Population	Exposure	Outcome
Childhood or paediatric onset diabetes or	Early diabetes control or HbA1c	Diabetic or diabetes complications or complications or side effects or adverse
juvenile diabetes diagnosis or newly	trajectories or HbA1c trends or glycaemic	events or acute complications or chronic complications or
diagnosed children or young persons or	trajectories or glycosylated or HbA1c or	glycaemia or hyper glycaemia or hypo glycaemia or ketosis or diabetic
young people or children or young or	A1c or Hemoglobin A or HbA(1c) level or	ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or
adolescent or teen or youth or adult T1D	glycaemic control or glucose control or	autoimmune disease or urine albumin or urine albumin creatinine ratio or
patient or type 1 diabetes or T1D or type 1	diabetes control or early intensive	urine albumin excretion or microalbuminuria or macroalbuminuria or renal
diabetes mellitus or T1DM or DM1 or type	intervention or intensive or conventional	disease or diabetic nephropathy or nephropathy or dialysis or foot ulcer or
1 or IDDM or insulin dependent or non-	or standard or regular or optimised or	amputation or retinopathy or blindness or vascular disease or vascular
insulin dependent or childhood onset	tight control or strict control or usual or	complications or microvascular disease or microvascular complications or
diabetes or childhood onset T1D or auto-	routine or therapy or treatment or	macrovascular disease or macrovascular complications or cardiovascular
immune or autoimmune or sudden onset	intervention or management or insulin	disease or MI or myocardial infarction or stroke or coronary artery disease or
or uncontrolled or labile or brittle	use or injection or dose insulin injections	cerebrovascular disease or peripheral vascular disease or blood pressure or BP
	or intensive therapy or insulin pump	or statin or death or mortality or Pathology or metabolism or metabolic
		memory

Additional File 1: Search Strategy for research questions: Impact of early glycaemic control on long-term HbA1c and risk of complications.

Additional File 2: Electronic database search strategy

Ι.	Scopus (via Elsevier) (Original: 17/12/2014; Updated: 17/02/2017)
1.	(TITLE-ABS-KEY (({early intensive} OR tight OR glycemic OR glycaemic OR glucose OR diabetes OR strict) W/2 control) OR TITLE-ABS-KEY (insulin W/2 (use* OR injection* OR dose* OR pump*)) OR TITLE-ABS-KEY (glycosylat* OR {HbA1c} OR a1c OR hemoglobin a OR haemoglobin OR {HbA(1c)}) OR TITLE-ABS-KEY ((intensive OR conventional OR standard OR regular OR optimised OR usual OR routine) W/2 (care OR treatment OR therapy OR intervention OR management)) OR TITLE-ABS-KEY (hyperglycaemia OR hypoglycaemia)) AND (TITLE-ABS-KEY OR ({Diabetes complication* } OR {side effects} OR {adverse events} OR glycemia OR glycaemia OR {hyper glycaemia} OR {hyper glycaemia} OR hyperglycaemia OR {hypoglycaemia} OR {hypor glycaemia} OR {hypoglycaemia} OR
2	TITLE-ABS-KEY (metabolism OR {metabolic memory})

3	(TITLE-ABS-KEY or ({Diabetes complication*} or {side effects} or {adverse events} or glycemia or glycaemia or {hyper glycemia} or {hyper glycaemia} or hyperglycaemia or hyperglycaemia) or TITLE-ABS-KEY (ketosis or {diabetic ketoacidosis} or DKA or {nonketotic hyperosmolar coma} or {insulin resistance} or {autoimmune disease*} or {auto immune disease}) or TITLE-ABS-KEY (ketosis or {liabetic ketoacidosis} or DKA or arcoalbuminuria or {renal disease*} or {kidney disease*} or {diabetic nephropathy} or nephropathy or dialysis) or TITLE-ABS-KEY ({foot ulcer} or amputation) or TITLE-ABS-KEY (retinopathy or blindness or {cardiovascular disease*} or MI or {myocardial infarction*} or stroke* or {coronary artery disease*}) or TITLE-ABS-KEY ({cerebrovascular disease*} or {blood pressure} or BP or statin* or death or mortality))
4	(TITLE-ABS-KEY (({early intensive} or tight or glycemic or glycaemic or glucose or diabetes or strict) W/2 control) OR TITLE-ABS-KEY (insulin W/2 (use* or injection* or dose* or pump*)) OR TITLE-ABS-KEY (glycosylat* or {HbA1c} or A1c or Hemoglobin A or haemoglobin or {HbA(1c)}) OR TITLE-ABS-KEY ((intensive or conventional or standard or regular or optimised or usual or routine) W/2 (care or treatment or therapy or intervention or management)) OR TITLE-ABS-KEY (hyperglycaemia or hypoglycaemia))
5	(TITLE-ABS-KEY (pediatric OR paediatric OR child* OR {young people} OR youth OR {young adult*} OR juvenile OR {insulin dependent} OR labile OR brittle OR {sudden onset} OR autoimmune OR {auto immune} OR {non insulin dependent} OR uncontrolled OR {newly diagnosed} OR {new diagnosis} OR {inception diabetes})
6	(TITLE-ABS-KEY (dm1 OR {diabetes mellitus 1} OR {diabetes mellitus} W/2 {type 1}) OR t1d OR t1dm OR iddmor {type 1})

١١.	Cochrane Library (Original: 17/12/2014; Updated: 17/02/2017)
#1	MeSH descriptor: [Diabetes Mellitus, Type 1] explode all trees
#2	DM1 or diabetes mellitus 1 or diabetes mellitus type 1 or T1D or T1DM or IDDM
#3	type 1 or paediatric or child or young people or youth or young adults or juvenile or insulin dependent or labile or brittle or sudden onset or autoimmune or auto immune or non insulin dependent or uncontrolled or newly diagnosed or new diagnosis or inception diabetes
#4	#1 or #2 or #3
#5	MeSH descriptor: [Blood Glucose] explode all trees
#6	MeSH descriptor: [Hemoglobin A, Glycosylated] explode all trees
#7	MeSH descriptor: [Hypoglycemia] explode all trees
#8	MeSH descriptor: [Hyperglycemia] explode all trees
#9	#5 or #6 or #7 or #8

#10	early intensive or tight or glycemic or glucose or diabetes or strict control
#11	insulin use or injection or dose or pump
#12	glycosylate or HbA1c or A1c or Hemoglobin A or HbA1c
#13	intensive or conventional or standard or regular or optimised or usual or routine care or treatment or therapy or intervention or management
#14	#9 or #10 or #11 or #12 or #13
#15	MeSH descriptor: [Diabetes Complications] explode all trees
#16	adverse effects or complications
#17	MeSH descriptor: [Ketosis] explode all trees
#18	MeSH descriptor: [Insulin Resistance] explode all trees
#19	MeSH descriptor: [Autoimmune Diseases] explode all trees
#20	MeSH descriptor: [Albuminuria] explode all trees
#21	MeSH descriptor: [Kidney Diseases] explode all trees
#22	MeSH descriptor: [Dialysis] explode all trees
#23	MeSH descriptor: [Blindness] explode all trees
#24	MeSH descriptor: [Cardiovascular Diseases] explode all trees
#25	MeSH descriptor: [Cerebrovascular Disorders] explode all trees
#26	MeSH descriptor: [Blood Pressure] explode all trees
#27	MeSH descriptor: [Hydroxymethylglutaryl-CoA Reductase Inhibitors] explode all trees
#28	MeSH descriptor: [Mortality] explode all trees

#29	Diabetes complications or side effects or adverse events or glycaemia or hyper glycaemia or hypo glycaemia or ketosis or diabetic ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease or urine albumin or urine albumin creatinine ratio or urine albumin excretion or microalbuminuria or macroalbuminuria or renal disease or diabetic nephropathy or nephropathy or dialysis or foot ulcer or amputation or retino pathy or blindness or cardiovascular disease or MI or myocardial infarction or stroke or coronary artery disease or cerebrovascular disease or peripheral vascular disease or blood pressure or BP or statin or death or mortality
#30	#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29
#31	metabolism
#32	metabolic memory
#33	#31 or #32
#34	#4 and #9 and #14 and #30 and #33

III.	CINAHL Plus (via EBSCO) (Original: 16/12/2014; Updated: 17/02/2017)
S34	S4 AND S14 AND S30 AND S33
S33	S31 OR S32
S32	"metabolic memory"
S31	MJ metabolism
S30	S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29
S29	diabetes complication or diabetes complication* or side effects or adverse events or glyc#emia or hyper glyc#emia or hyperglyc#emia or hypoglyc#emia or ketosis or diabetic ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease* or urine albumin or microalbuminaria or macroalbuminuria or renal disease* or kidney disease* or diabetic nephropathy or nephropathy or dialysis or foot ulcer or amputation or retinopathy or blindness or cardiovascular disease* or MI or myocardial infarction* or stroke* or coronary artery disease* or cerebrovascular disease* or peripheral vascular disease* or blood pressure or BP or statin* or death or mortality
S28	(MH "mortality+")
S27	(MH "statins+")

S26	(MH "blood pressure+")
S25	(MH "cerebrovascular disorders+")
S24	(MH "stroke+")
S23	(MH "cardiovascular diseases+")
S22	(MH "blindness+")
S21	(MH "dialysis+")
S20	(MH "kidney diseases+")
S19	(MH "Albuminuria")
S18	(MH autoimmune diseases+)
S17	(MH insulin resistance+)
S16	(MH "diabetic angiopathies+") OR (MH "diabetic cardiomyopathies") OR (MH "diabetic coma+") OR (MH "diabetic ketoacidosis") OR (MH "diabetic neuropathies+")
S15	(MH "diabetes mellitus/co")
S14	S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
S13	(intensive OR conventional OR standard OR regular OR optimi#ed OR usual OR routine) N2 (care OR treatment OR therapy OR intervention OR management)
S12	glycosylat* OR HbA1c OR A1c OR H#emoglobin A OR HbA#1c
S11	insulin N2 (use* OR injection* OR dose* OR pump*)
S10	("early intensive" OR tight OR glyc#emic OR glucose OR diabetes or strict) N2 control)
S9	(MH "Hyperglycemia+")
S8	(MH "Hypoglycemia+")
S7	MH blood glucose
S6	MH hemoglobin A, glycosylated
S5	(MH "Glycemic Control")
S4	S1 OR S2 OR S3
S3	("type 1" OR p#ediatric OR child* OR "young people" OR youth OR "young adult" OR juvenile OR "insulin dependent" OR labile OR brittle OR "sudden onset" OR
55	autoimmune OR "auto immune" OR "non insulin dependent" OR uncontrolled OR "newly diagnosed" OR "new diagnosis" OR inception) N5 diabetes
S2	DM1 OR "diabetes mellitus 1" OR ("diabetes mellitus" N2 type 1) OR T1D or T1DM or IDDM
S1	(MH "Diabetes Mellitus, Type 1+")

IV.	Web of Science (via Thomson Reuters) (Original: 16/12/2014; Updated: 17/02/2017)
1	TOPIC: ((DM1 OR "diabetes mellitus 1" OR ("diabetes mellitus" NEAR/2 "type 1") OR T1D or T1DM or IDDM) OR TOPIC: (("type 1" OR p\$ediatric OR child* OR "young people" OR youth OR "young adult" OR juvenile OR "insulin dependent" OR labile OR brittle OR "sudden onset" OR autoimmune OR "auto immune" OR "non insulin dependent" OR uncontrolled OR "newly diagnosed" OR "new diagnosis" OR inception) NEAR/5 diabetes)) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years

2	TOPIC: (TOPIC: (("early intensive" OR tight OR glyc\$emic OR glucose OR diabetes or strict) NEAR/2 control) OR TOPIC: (insulin NEAR/2 (use* OR injection* OR dose* OR pump*)) OR TOPIC: (glycosylat* OR HbA1c OR A1c OR H\$emoglobin A OR HbA\$1c) OR TOPIC: ((intensive OR conventional OR standard OR regular OR optimi\$ed OR usual OR routine) NEAR/2 (care OR treatment OR therapy OR intervention OR management)) OR TOPIC: (hyperglyc\$emia OR hypoglyc\$emia)) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years
3	TOPIC: ("Diabetes complication*" OR "side effects" OR "adverse events" OR glyc\$emia OR "hyper glyc\$emia" OR hyperglyc\$emia OR "hypo glyc\$emia" OR hypoglyc\$emia OR ketosis OR "diabetic ketoacidosis" OR DKA OR "nonketotic hyperosmolar coma" OR "insulin resistance" OR "autoimmune disease*" OR "auto immune disease" OR "urine albumin" OR microalbuminaria OR macroalbuminuria OR "renal disease*" OR "kidney disease*" OR nephropathy OR dialysis OR "foot ulcer" OR amputation OR retinopathy OR blindness OR "cardiovascular disease*" OR MI OR "myocardial infarction*" OR stroke* OR "coronary artery disease*" OR "cerebrovascular disease*" OR "blood pressure" OR BP OR statin* OR death OR mortality)) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years
4	TOPIC: (TOPIC: (metabolism OR "metabolic memory" OR metabolic)) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years
5	#4 AND #3 AND #2 AND #1 DocType=All document types; Language=All languages;

v.	EMBASE (via OVID) (Original: 16/12/2014; Updated: 17/02/2017)
1	exp insulin dependent diabetes mellitus/
2	(DM1 or diabetes mellitus 1 or (diabetes mellitus adj2 type 1) or T1D or T1DM or IDDM).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading]
3	((type 1 or p?ediatric or child* or young people or youth or young adults or juvenile or insulin dependent or labile or brittle or sudden onset or autoimmune or auto immune or non insulin dependent or uncontrolled or newly diagnosed or new diagnosis or inception) adj5 diabetes).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading]
4	1 or 2 or 3
5	exp glycosylated hemoglobin/
6	exp glucose blood level/
7	exp hypoglycemia/
8	exp hyperglycemia/
7 exp hypoglycemia/ 8 exp hyperglycemia/ 9 ((early intensive or tight or glyc?emic or glucose or diabetes or strict) adj2 control).mp. [mp=title, abstract, heading word, drug trade name, original title, devic manufacturer, drug manufacturer, device trade name, keyword, floating subheading]	
10	(insulin adj2 (use* or injection* or dose* or pump*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading]
11	(glycosylat* or HbA1c or A1c or H?emoglobin A or HbA?1c).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading]

ŀ	((intensive or conventional or standard or regular or optimi?ed or usual or routine) adj2 (care or treatment or therapy or intervention or management)).mp.
12	[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading]
13	5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
15	diabetic angiopathy/ or diabetic cardiomyopathy/ or diabetic coma/ or diabetic foot/ or diabetic hypertension/ or diabetic ketoacidosis/ or diabetic macular edema/
14	or diabetic nephropathy/ or diabetic neuropathy/ or diabetic obesity/ or diabetic retinopathy/ or impaired glucose tolerance/ or "maternally inherited diabetes and
	deafness"/ or nonketotic diabetic coma/ or wolfram syndrome/
15	exp diabetes mellitus/co [Complication]
16	exp diabetes mellitus/si [Side Effect]
17	exp insulin resistance/
18	exp autoimmune disease/
19	exp albuminuria/
20	exp kidney disease/
21	exp dialysis/
22	exp blindness/
23	exp cardiovascular disease/
24	exp cerebrovascular disease/
25	exp blood pressure/
26	exp hydroxymethylglutaryl coenzyme A reductase inhibitor/
27	exp mortality/
	(Diabetes complication* or side effects or adverse events or glyc?emia or hyper glyc?emia or hyperglyc?emia or hypo glyc?emia or hypoglyc?emia or ketosis or diabetic ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease* or urine albumin or microalbuminaria or
ľ	macroalbuminuria or renal disease* or kidney disease* or diabetic nephropathy or nephropathy or dialysis or foot ulcer or amputation or retinopathy or blindness
28	or cardiovascular disease* or MI or myocardial infarction* or stroke* or coronary artery disease* or cerebrovascular disease* or peripheral vascular disease* or
ľ	blood pressure or BP or statin* or death or mortality).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug
ľ	manufacturer, device trade name, keyword, floating subheading]
29	14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30	memory/
	metabolic memory.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword,
31	floating subheading]
32	30 or 31
33	4 and 13 and 29 and 32

1	exp Diabetes Mellitus, Type 1/
	(((DM1 or diabetes mellitus 1 or diabetes mellitus) adj2 type 1) or T1D or T1DM or IDDM).mp. [mp=title, abstract, original title, name of substance
2	word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique
	identifier, synonyms]
	((type 1 or p?ediatric or child* or young people or youth or young adults or juvenile or insulin dependent or labile or brittle or sudden onset or
3	autoimmune or auto immune or non insulin dependent or uncontrolled or newly diagnosed or new diagnosis or inception) adj5 diabetes).mp.
5	[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare
	disease supplementary concept word, unique identifier, synonyms]
4	1 or 2 or 3
5	exp Blood Glucose/
6	hemoglobins/ or hemoglobin a, glycosylated/
7	exp Hypoglycemia/
8	exp Hyperglycemia/
	((early intensive or tight or glyc?emic or glucose or diabetes or strict) adj2 control).mp. [mp=title, abstract, original title, name of substance word,
9	subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier,
	synonyms]
10	(insulin adj2 (use* or injection* or dose* or pump*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
10	heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
11	(glycosylat* or HbA1c or A1c or H?emoglobin A or HbA?1c).mp. [mp=title, abstract, original title, name of substance word, subject heading word,
11	keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
11	((intensive or conventional or standard or regular or optimi?ed or usual or routine) adj2 (care or treatment or therapy or intervention or
	management)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
	concept word, rare disease supplementary concept word, unique identifier, synonyms]
13	5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14	exp Diabetes Complications/
15	adverse effects.fs.
16	complications.fs.
17	exp Ketosis/
18	exp Insulin Resistance/
19	exp Autoimmune Diseases/
20	exp Albuminuria/
21	exp Kidney Diseases/

22	exp Dialysis/
23	exp Blindness/
24	exp Cardiovascular Diseases/
25	exp Cerebrovascular Disorders/
26	exp Blood Pressure/
27	exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/
28	exp Mortality/
29	(Diabetes complications or side effects or adverse events or glycaemia or hyper glycaemia or hypo glycaemia or ketosis or diabetic ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease or urine albumin or urine albumin creatinine ratio or urine albumin excretion or microalbuminuria or macroalbuminuria or renal disease or diabetic nephropathy or nephropathy or dialysis or foot ulcer or amputation or retinopathy or blindness or cardiovascular disease or MI or myocardial infarction or stroke or coronary artery disease or cerebrovascular disease or peripheral vascular disease or blood pressure or BP or statin or death or mortality).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
30	14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
31	4 and 13 and 30
32	metabolism.fs.
33	metabolic memory.mp.
34	32 or 33
35	31 and 34

Additional File 3: Inclusion and exclusion criteria for review of evidence on effect of early HbA1c levels on glycaemic trends and later complications

Inclusion Criteria	Exclusion Criteria
- Interventional studies (RCT's and non-RCT's) targeting glycaemic control (within 2	- Non-human studies
years of diagnosis of T1D) and described an association with health outcomes	- Selection of population based on other diseases/co-morbidities
- Non-intervention/observational i.e. cohort and cross sectional (XS) studies that	- Adults aged more than 19 years at baseline.
quantified the association between early glycaemic control (within 2 years of diagnosis	- Studies on T2D
of T1D) AND risk of future complications in children and young people aged 0 to 19	- Quantitative studies not reporting clinical outcomes
years at baseline	- Quantitative studies that measured glycaemic control but did not describe an
	association with outcome variables
 longitudinal studies with a follow-up of ≥ 5 years from diagnosis 	

Observational/Non-intervention studies (cross-sectional and longitudinal)	
- Study id	
- Author	
- Year	
- Country	
- Age Range	
- Average age	
- Sex (Male: Female ratio)	
- Ethnicity	
- Socioeconomic status	
- Design (Cross sectional/longitudinal)	
- Number of participants	
 Sample/recruitment e.g general population representative sample or specialist groups, 	
- Exposure examined	
- Measurement of Exposure	
 Measurement conducted by Level of glycaemic control 	
 Setting (home, primary care, secondary care) 	
- Outcome (HbA1c levels, complications, HbA1c tracking/metabolic memory - separate row for each	outcome
investigated),	
- Measurement of outcome (objective)	
- Analysis	
- Effect	
- Author email	
- Comments	

Additional File 4: Details of data extracted from included studies

Additional File 5: Quality assessment criteria


For observational (prospective/retrospective cohort and cross sectional) studies				
Total quality assessment score (maximum of 6) was derived for fulfilment of following criteria:				
1) More than 50 participants analysed;				
2) Studies representing general population				
3) Prospective study design				
4) Adjusted/multivariate analysis				

5) Objective measure of outcome6) Objective measure of exposure.

Supplementary Fig 1: Summary of FE & RE models: Estimated SMD of HbA1c with 95%CI, between the low (exposed to glycaemic control) and high (unexposed) HbA1c groups during various time-points of follow-up (Sensitivity analysis - without Shalitin et al 2012)

HbA1c after 1 year Lawes 2014 Scotland, UK 7.8±3.4 -0.90 (-1.35, -0.45) 27, 7.1 (2.1) 87, 9.2 (2.4) 5.26 8.15 Samuelsson 2014 Sweden 13.9±2.5 -0.78 (-0.89, -0.68) 655, 7 (2) 856, 8.7 (2.3) 94.74 7.85 I-V Subtotal -0.79 (-0.89, -0.69) 662 943 100.00 D+L Subtotal -0.79 (-0.89, -0.69) 682 943 100.00	Study	Country	Age_at_diagnosis		SMD (95% CI)	N, mean (SD); HbA1c <7%	N, mean (SD); HbA1c >7%	% Weight (I-V)	Mean_HbA1c
V Matherinal (sequence $4 - 5x_0 = 1$) $1, 10 + 15, 4, 250$ 2^{-7} $1, 10 + 15, 4, 250$ 2^{-7} $10, 0, 0^{-7}$ Math Caller 1 year Math Caller 1 year $0, 0^{-7}$ 0^{-7} $0, 0^{-7}$ <			7.8†3.4	_	-1.10 (-1.56, -0.65)	27. 6.8 (2.1)	87, 9.2 (2.2)	100.00	8
Hart a first 1 yer Harves 2014 Sociand, UK 7.351.4 Samuelson 2014 Sociand, UK 7.351.4 Mark a first 2 year Image 3014 Sociand, UK 7.351.4 Mark a first 2 year Image 3014 Sociand, UK 7.351.4 Mark a first 2 year Image 3014 Sociand, UK 7.851.4 7.85 Nameliance 2014 Sociand, UK 7.851.4 5.85 6.65 Nameliance 2014 Sociand, UK 7.851.4 5.85 6.65 Nameliance 2014 Sociand, UK 7.851.4 5.85 6.65 6.65 Nameliance 2014 Sociand, UK 7.851.4 5.95 7.95 6.05 6.65 Nameliance 2014 Sociand, UK 7.851.4 5.95 7.95 6.05 6.65 Nameliance 2014 Sociand, UK 7.851.4 5.95 7.71 6.06.5 6.65 Nameliance 2014 Sociand, UK 7.851.4 5.95 7.29 8.95 Nameliance 2014 Sociand, UK 7.851.4 5.95 7.29 8.95 Nameliance 2014 Sociand, UK			\sim						-
Laves 2014 Scattand, UK 7,433.4 Samuelsan 2014	D+L Subtotal		\diamond		-1.10 (-1.56, -0.65)				
Samuelssen 2014 Sweden $13.92.5$ V 4.76 (4.39 , 4.69) 955 , $7(2)$ 856 , $57(2.3)$ 8.74 7.85 Waht a filer 2 years 4.76 (4.39 , 4.89) 682 955 , $7(2.3)$ 8.74 7.85 Wasse 2014 Socitand, UK $7.83.4$ 4.76 (4.39 , 4.89) 682 955 , $7(2.3)$ 8.74 7.85 Mat c after 2 years 4.76 (4.29 , 4.89) 565 , 657 (5.5) 7.85 , 8.8 (2.4) 5.355 7.85 Mat c after 3 years 4.76 (4.39 , 4.39) 575 705 705 705 705 100.00 75 Mat c after 5 years 4.966 (4.13 , 4.251 7.85 , $61(8.5)$ $58, 57(2.3)$ 8.57 , 12.9 8.55 $7.7(2.3)$ 7.85 4.27 10.000 777 700.00 777 700.00 777 777 100.00 777 777 777 777 772 100.00 772 100.00 772 100.00 772 100.00 772 100.00 772 100.00 772 100.00 772 100.00 <t< td=""><td>HbA1c after 1 ye</td><td>ar</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	HbA1c after 1 ye	ar							
N Babtotati (Jequared = 0.0%, $p = 0.614$) 4.79 [4.89, 4.69 982 943 100.00 N Babtotati (Jequared = 0.0%, $p = 0.614$) 4.79 [4.89, 4.69 982 943 100.00 N Babtotati (Jequared = 0.0%, $p = 0.728$) 4.79 [4.89, 4.69 957, 51, 51, 51, 51, 51, 51, 51, 51, 51, 51	Lawes 2014		•		-0.90 (-1.35, -0.45)	27, 7.1 (2.1)	87, 9.2 (2.4)		8.15
Dr. I. Subtral -73° (-0.85, -0.89) HbA fc. after 2 years	Samuelsson 2014	Sweden	13.9±2.5	-	-0.78 (-0.89, -0.68)	655, 7 (2)	856, 8.7 (2.3)	94.74	7.85
that c after 2 years the field of the 2 years twens 2014 Sociationi, UK 7, 83.4, 53.2,5 V Subtotal twens 2014 Sociationi, UK 7, 83.4, 53.2,5 V Subtotal the field of 3 years twens 2014 Sociationi, UK 7, 83.4, 53.2,5 V Subtotal the field of 3 years twens 2014 Sociationi, UK 7, 83.4, 53.2,5 V Subtotal that 1 after 3 years twens 2014 Sociationi, UK 7, 83.4, 53.2,5 V Subtotal that 1 after 3 years twens 2014 Sociationi, UK 7, 83.4, 53	I-V Subtotal (I-so	uared = 0.0%, p =	0.614)		-0.79 (-0.89, -0.69)	682	943	100.00	
Lawes 2014 Scotland, UK 7.82.4 Banuelsson 2014 Swedon $3.32.5$ Vb Subtrol (Vs. p = 0.728) Dri Subtrol 3 HAfc after 3 years Lawes 2014 Scotland, UK 7.82.4 Banuelsson 2014 Swedon $3.32.5$ Vb Subtrol (Vs. p = 0.328) Dri Subtrol 3 HAfc after 5 years Clements 2014 USA 9.024.1 Banuelsson 2014 Swedon $3.32.5$ Vb Subtrol (Vs. p = 0.328) Dri Subtrol 3 HAfc after 5 years Clements 2014 Scotland, UK 7.82.3.4 Banuelsson 2014 Swedon $3.32.5$.5 Vb Subtrol (Vs. p = 0.328) Dri Subtrol 3 HAfc after 7 years Lawes 2014 Scotland, UK 7.82.3.4 Banuelsson 2014 Swedon $3.32.5$.5 Vb Subtrol (Vs. p = 0.328) Dri Subtrol 3 HAfc after 7 years Lawes 2014 Scotland, UK 7.82.3.4 Banuelsson 2014 Swedon $3.32.5$.5 Vb Subtrol (Vs. p = 0.328) Dri Subtrol 3 HAfc after 7 years Lawes 2014 Scotland, UK 7.82.3.4 Banuelsson 2014 Swedon $3.32.5$.5 Vb Subtrol (Vs. p = 0.328) Dri Subtrol 3 HAfc after 10 years Lawes 2014 Scotland, UK 7.82.3.4 Banuelsson 2014 Swedon $3.32.5$.5 Vb Subtrol (Vs. p = 0.328) Dri Subtrol 3 HAfc after 10 years Lawes 2014 Scotland, UK 7.82.3.4 Banuelsson 2014 Swedon $3.32.5$.5 Vb Subtrol (Vs. p = 0.374) Dri Subtrol 3 HAfc after 10 years Lawes 2014 Scotland, UK 7.82.3.4 Scotland, Scotland, Scotland, Scotland, Scotland, Sc	D+L Subtotal		¢		-0.79 (-0.89, -0.69)				
Samuelsaon 2014 Sweden 13.92.3 V4 Subtotal (Lequared = 0.0%, p = 0.728) D4 Subtotal Sweden 13.92.5 V4 Subtotal (Laquared = 0.0%, p = 0.728) D4 Subtotal Sweden 13.92.5 V4 Subtotal (Lequared = 0.0%, p = 0.528) D4 Subtotal (Lequared = 0.0%, p = 0.528) D4 Subtotal (Lequared = 0.0%, p = 0.528) D4 Subtotal (Lequared = 0.5%, p = 0.598) D4 Subtotal (Lequared = 0.5%, p = 0.599) D4 Subtotal (Lequared = 0.5%, p = 0.574) D4 Subtotal (Lequared = 0.5%, p = 0.674) D4 Subtotal (Lequared = 0	HbA1c after 2 ye	ars							
Lives 2014 Scotland, UK 7.83.4 Samuelsson 2014 Scotland, UK 7.83.4 V Subtoral $-0.78 (0.28, 0.457)$ 570 875 100.00 $-0.78 (0.28, 0.457)$ 570 875 100.00 $-0.78 (0.28, 0.457)$ 570 875 100.00 $-0.78 (0.28, 0.457)$ 570 875 100.00 $-0.78 (0.28, 0.457)$ 570 875 100.00 $-0.78 (0.28, 0.457)$ 570 875 100.00 $-0.78 (0.28, 0.457)$ 570 875 100.00 $-0.78 (0.28, 0.457)$ 570 875 100.00 $-0.52 (0.37, 0.08)$ $455, 71.20$ $57, 872$ 8.55 $-0.52 (0.37, 0.08)$ $452, 91.1(1.8)$ $653, 9.5 (1.8)$ 51.34 9.25 $-0.52 (0.37, 0.08)$ $252, 9.1 (1.8)$ $653, 9.5 (1.8)$ 51.34 9.25 $-0.52 (0.37, 0.08)$ $252, 9.1 (1.8)$ $653, 9.5 (1.8)$ 51.34 9.25 $-0.52 (0.37, 0.49)$ $248, 73 (2.3)$ $23, 8.0 (2.3)$ 44.6 8.1 $-0.52 (0.47, 0.47)$ <td< td=""><td>Lawes 2014</td><td>•</td><td>•</td><td>_ </td><td></td><td></td><td></td><td></td><td></td></td<>	Lawes 2014	•	•	_					
be L Subtotal HbA1C after 3 years Lawes 2014 Scotland, UK 7.853.4 Samuelisson 2014 Sweden 13.922.5 VS Subtotal HbA1C after 5 years Lorents 2014 Sociand, UK 7.853.4 Samuelisson 2014 Sweden 13.922.5 VS Subtotal HbA1C after 5 years Lawes 2014 Scotland, UK 7.853.4 Samuelisson 2014 Sweden 13.922.5 VS Subtotal HbA1C after 10 years Lawes 2014 Sweden 13.922.5 VS Subtotal HbA1C after 10 years Law	Samuelsson 2014	Sweden	13.9±2.5	-	-0.78 (-0.89, -0.67)	543, 6.9 (2.5)			7.85
HbA1c after 3 years Lawes 2014 Scotland, UK 7.813.4 Simulesson 2014 Sweden 13.822.5 IV Subtotal (Lequared = 0.0%, p = 0.928) OL Subtotal HbA1c after 5 years Demonts 2014 Scotland, UK 7.813.4 Simulesson 2014 Sweden Size_25 IV Subtotal HbA1c after 7 years Image: Scotland, UK 7.813.4 Lawes 2014 Scotland, UK 7.813.4 Samuelsson 2014 Sweden I (Lequared = 85.7%, p = 0.001) Image: Scotland, UK 7.813.4 OL Subtotal Image: Scotland, UK 7.813.4 HbA1c after 7 years Image: Scotland, UK 7.813.4 Lawes 2014 Scotland, UK 7.813.4 Samuelsson 2014 Sweden Subtotal Image: Scotland, UK 7.813.4 HbA1c after 10 years Image: Scotland, UK 7.813.4 Lawes 2014 Scotland, UK 7.813.4 Samuelsson 2014 Sweden Lawes 2014 Scotland, UK 7.813.4 Samuelsson 2014 Sweden Lawes 2014 Scotland, UK 7.813.4 Samuelsson 2014 Sweden Lawes 2014 <t< td=""><td></td><td>uared = 0.0%, p =</td><td>0.728)</td><td></td><td>-0.78 (-0.89, -0.67)</td><td>570</td><td>875</td><td>100.00</td><td></td></t<>		uared = 0.0%, p =	0.728)		-0.78 (-0.89, -0.67)	570	875	100.00	
Lawes 2014 Socitand, UK 7.823.4 Samuelsson 2014 Sweden 13.92.5 LV Subtotal Image: Social Social (Liquared = 0.0%, p = 0.928) Doi Subtotal Image: Social Social (Liquared = 0.0%, p = 0.928) MAIC after 5 years Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal Image: Social Social (Liquared = 85.7%, p = 0.001) Doi: Subtotal I	D+L Subtotal		¢	>	-0.78 (-0.89, -0.67)				
Samuelsson 2014 Sweden 13.922.5 IV Subtotal 0.71 (0.83, 0.59) 455, 7.7 (2) 655, 8.7 (2.4) 92.71 7.9 HA1C after 5 years 0.671 (0.83, 0.59) 462 772 100.00 9.25 Clements 2014 USA 9.024.1 0.71 (0.83, 0.59) 462 772 100.00 9.25 Lawse 2014 Scotland, UK 7.853.4 Samuelsson 2014 Sweden 13.922.5 100.00 11.9 9.25 VS Subtotal 0.22 (0.37, 0.08) 262, 9.1 (1.8) 663, 9.5 (1.8) 51.34 9.2 HbA1c after 7 years 0.62 (0.478, 0.477) 248, 7.3 (2.5) 523, 8.9 (2.6) 44.46 8.1 Lwess 2014 Scotland, UK 7.853.4 0.41 (0.73, 0.09) 17, 8.8 (1.5) 41, 9.8 (2.2) 12.08 9.3 Samuelsson 2014 Sweden 13.922.5 100.00 1245 100.00	-								
LV Subtotal 0.71 (0.83, 0.59) 462 772 100.00 Dri Subtotal 0.71 (0.83, 0.59) 462 772 100.00 HA/A c after 5 years 0.71 (0.83, 0.59) 462 772 100.00 Lawes 2014 Soctiand, UK 7.813.4 51.34 52. 59, 9.7 (2.3) 419 9.25 V Subtotal -0.38 (0.68, 0.12) 21, 8.8 (2.5) 59, 9.7 (2.3) 419 9.25 V Subtotal -0.38 (0.68, 0.47) 249, 7.3 (2.5) 523, 8.9 (2.6) 44.46 8.1 V Subtotal -0.41 (0.51, -0.30) 532 1245 100.00 -0.41 (0.73, -0.09) -0.41 (0.73, -0.09) -0.41 (0.73, -0.09) -0.41 (0.73, -0.09) -0.41 (0.73, -0.09) -0.41 (0.73, -0.09) -0.41 (0.73, -0.09) -0.41 (0.73, -0.09) -0.41 (0.73, -0.09) -0.41 (0.73, -0.99) -0.42 (0.97, -0.54) 122, 7.3 (2) 343, 9.1 (2.5) 87.92 8.2 V Subtotal -0.59 (0.97, -0.54) 122, 7.3 (2) 343, 9.1 (2.5) 87.92 8.2 -0.72 (0.92, -0.53) 139 384 100.00 -0.72 (0.92, -0.53) 139 384 100.00 -0.42 (0.63, -0.62) 55 -0.32 (0.63, -0.62				•					
b+L Subtotal 0.77 (0.83, 0.59) HbA1c after 5 years 0.80 (0.23, 0.059) Lawes 2014 USA 9.024.1 Lawes 2014 Scotland, UK 7.833.4 Samuelsson 2014 Sweden 13.922.5 LV Subtotal									7.9
HbA1c after 5 years Clements 2014 USA 9.0±4.1 Lawes 2014 Sottland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 V Subtotal (I-6,1,0,0,0) 522, 9.1 (1.8) 663, 9.5 (1.8) 51.34 9.2 HbA1c after 7 years -0.22 (0.37, -0.08) 262, 9.1 (1.8) 663, 9.5 (1.8) 51.34 9.2 Lawes 2014 Soctland, UK 7.8±3.4 -0.38 (0.40, 0.12) 21, 8.8 (1.5) 41, 9.8 (2.2) 12.08 9.3 Binuelsson 2014 Sweden 13.9±2.5 -0.49 (1.07, 0.08) 17, 8.8 (1.5) 41, 9.8 (2.2) 12.08 9.3 Jost 2014 Sweden 13.9±2.5 -0.49 (1.07, 0.08) 17, 8.8 (1.5) 41, 9.8 (2.2) 12.08 9.3 Jamuelsson 2014 Sweden 13.9±2.5 -0.72 (0.92, -0.53) 139 38.4 100.00 V Subtotal I-super 2014 Soctland, UK 7.8±3.4 -0.35 (0.67, 0.62, 49, 8.4 (2.6) 14.9, 9.2.6 8.82 8.55 Lawes 2014 Soctland, UK 7.8±3.4 -0.35 (0.67, 0.02, 49, 8.1 (2.6) 14.4, 9.2.6 8.82 8.55 LW Subtotal I-super 20.0%, p = 0.674) <td>•</td> <td>uared = 0.0%, p =</td> <td>0.928)</td> <td>2</td> <td></td> <td>462</td> <td>772</td> <td>100.00</td> <td></td>	•	uared = 0.0%, p =	0.928)	2		462	772	100.00	
Clements 2014 USA 9.024.1 Lawes 2014 Scotland, UK 7.823.4 Samuelsson 2014 Sweden 13.922.5 LV Subtotal (1-squared = 85.7%, p = 0.001) D-L Subtotal Scotland, UK 7.823.4 HbA1c after 7 years	D+L Subtotal		<	>	-0.71 (-0.83, -0.59)				
Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 IV Subtotal (Isquared = 85.7%, p = 0.001) D+L Subtotal HbA1c after 7 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.399) D+L Subtotal HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.399) D+L Subtotal HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.399) D+L Subtotal HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal HbA1c after 10 years Lawes 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal HbA1c after 10 years Lawes 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal HbA1c after 10 years Lawes 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal HbA1c after 10 years Lawes 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal HbA1c after 10 years Lawes 2014 Sweden 13.9±2.5 IV Subtotal (I-squared = 0.0%, p = 0.674) IV Subtotal (I-squared = 0.0%, p = 0.674) IV Subtotal	-								
Samuelsson 2014 Sveden 13.922.5 I-V Subtotal I-squared = 85.7%, p = 0.001) D+L Subtotal -0.62 (-0.78, -0.47) 249, 7.3 (2.5) 523, 8.9 (2.6) 44.46 8.1 HbA1c after 7 years -0.41 (-0.51, -0.30) 532 1245 100.00 Lawes 2014 Scotland, UK 7.8±3.4 -0.49 (-1.07, 0.08) 17, 8.8 (1.5) 41, 9.8 (2.2) 12.08 9.3 Samuelsson 2014 Sweden 13.9±2.5 -0.72 (-0.92, -0.53) 139 384 100.00 U-L Subtotal -0.41 (-1.06, 0.78) 6, 8.9 (4.3) 19, 9.3 (2.4) 11.18 9.1 HbA1c after 10 years -0.32 (-0.67, -0.02) 49, 8.1 (2.6) 144, 9 (2.6) 88.82 8.55 Lawes 2014 Scotland, UK 7.8±3.4 -0.35 (-0.67, -0.02) 49, 8.1 (2.6) 144, 9 (2.6) 88.82 8.55 U-Subtotal -0.32 (-0.63, -0.02) 55 163 100.00 -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
I-V Subtotal (I-squared = 85.7%, p = 0.001) Image: constraint of the squared in the square in the square in the square in the square in the									
D+L Subtotal -0.41 (-0.73, -0.09) HbA1c after 7 years -0.49 (-1.07, 0.08) 17, 8.8 (1.5) 41, 9.8 (2.2) 12.08 9.3 Samuelsson 2014 Sweden 13.9±2.5 -0.76 (-0.97, -0.54) 122, 7.3 (2) 343, 9.1 (2.5) 87.92 8.2 Iv Subtotal -0.72 (-0.92, -0.53) 139 384 100.00 D+L Subtotal -0.72 (-0.92, -0.53) 139 384 100.00 HbA1c after 10 years -0.14 (-1.06, 0.78) 6, 8.9 (4.3) 19, 9.3 (2.4) 11.18 9.1 Lawes 2014 Scotland, UK 7.8±3.4 -0.35 (-0.67, -0.02) 49, 8.1 (2.6) 144, 9 (2.6) 88.82 8.55 I-V Subtotal (I-squared = 0.0%, p = 0.674) -0.32 (-0.63, -0.02) 55 163 100.00 D+L Subtotal -0.32 (-0.63, -0.02) 55 163 100.00 -0.32 (-0.63, -0.02)				•					8.1
HbA1c after 7 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 LV Subtotal (I-squared = 0.0%, p = 0.399) Image: Control of the system of t		uared = 85.7%, p	= 0.001)	2		532	1245	100.00	
Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 I-V Subtotal (I-squared = 0.0%, p = 0.399) D+L Subtotal HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 I-V Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal D+L Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal (I-	D+L Subtotal			\sim	-0.41 (-0.73, -0.09)				
Samuelsson 2014 Sweden 13.9±2.5 I-V Subtotal (I-squared = 0.0%, p = 0.399) D+L Subtotal HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 I-V Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal D+L	-								
I-V Subtotal (I-squared = 0.0%, p = 0.399) Image: Constraint of the squared = 0.0%, p = 0.399) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.399) HbA1c after 10 years Image: Constraint of the squared = 0.0%, p = 0.674) Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 I-V Subtotal (I-squared = 0.0%, p = 0.674) Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.674) D+L Subtotal Image: Constraint of the squared = 0.0%, p = 0.			_						
D+L Subtotal -0.72 (-0.92, -0.53) HbA1c after 10 years -0.14 (-1.06, 0.78) 6, 8.9 (4.3) 19, 9.3 (2.4) 11.18 9.1 Lawes 2014 Scotland, UK 7.8±3.4 -0.14 (-1.06, 0.78) 6, 8.9 (4.3) 19, 9.3 (2.4) 11.18 9.1 Samuelsson 2014 Sweden 13.9±2.5 -0.35 (-0.67, -0.02) 49, 8.1 (2.6) 144, 9 (2.6) 88.82 8.55 I-V Subtotal -0.32 (-0.63, -0.02) 55 163 100.00 D+L Subtotal -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02) -0.32 (-0.63, -0.02)									8.2
HbA1c after 10 years Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 I-V Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal -0.32 (-0.63, -0.02) 55 163 100.00 -0.32 (-0.63, -0.02)		uared = 0.0%, p =	0.399)	~		139	384	100.00	
Lawes 2014 Scotland, UK 7.8±3.4 Samuelsson 2014 Sweden 13.9±2.5 I-V Subtotal II-Squared = 0.0%, p = 0.674) D+L Subtotal -0.14 (-1.06, 0.78) 6, 8.9 (4.3) 19, 9.3 (2.4) 11.18 9.1 -0.35 (-0.67, -0.02) 49, 8.1 (2.6) 144, 9 (2.6) 88.82 8.55 -0.32 (-0.63, -0.02) 55 163 100.00 -0.32 (-0.63, -0.02)	D+L Subtotal		<	>	-0.72 (-0.92, -0.53)				
Samuelsson 2014 Sweden 13.9±2.5 I-V Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal D+L Subtotal	-								
I-V Subtotal (I-squared = 0.0%, p = 0.674) D+L Subtotal -0.32 (-0.63, -0.02) 55 163 100.00 -0.32 (-0.63, -0.02)									
D+L Subtotal -0.32 (-0.63, -0.02)									8.55
		uared = 0.0%, p =	0.674)	\leq		55	163	100.00	
	D+L Subtotal			\sim	-0.32 (-0.63, -0.02)				
			<u> </u>						

SMD: standardised mean difference; CI: confidence interval; N: number of participants; SD: standard deviation; I-V: inverse variance; D+L: DerSimonian and Laird



Supplementary Fig 2: HbA1c trajectories by studies and estimated overall trajectory (using population mean and standard error)

Supplementary Fig 3: HbA1c trajectories by studies (High v/s low)

